THE JOURNAL OF CLINICAL PSYCHIATRY

Author Index to Volume 72: January 2011 Through December 2011

Abel KM see Laursen TM

Addington DE, Mohamed S, Rosenheck RA, Davis SM, Stroup TS, McEvoy JP, Swartz MS, Lieberman JA. Impact of second-generation antipsychotics and perphenazine on depressive symptoms in a randomized trial of treatment for chronic schizophrenia. Jan 75–80

Adler LA, Barkley RA, Newcorn JH. Performance improvement CME: adult ADHD. Apr e15

Adler LA, Newcorn JH. Administering and evaluating the results of the adult ADHD Self-Report Scale (ASRS) in adolescents. June e20

Adler LA, Newcorn JH. Assessing adolescents using ADHD rating scales. May e17

Agartz I see Steen NE

Agid O, Arenovich T, Sajeev G, Zipursky RB, Kapur S, Foussias G, Remington G. Algorithm-based approach to first-episode schizophrenia: response rates over 3 prospective antipsychotic trials with a retrospective data analysis. Nov 1439–1444

Ahn W-k see Rottman BM

Aitchison KJ see Mondelli V; Uher R

Alberich S see González-Pinto A

Albert MS see Reiman EM

Alder J see Wirz-Justice A

Alegría M see Polo AJ

Alesci S see Bonne O

Alexopoulos GS. Pharmacotherapy for late-life depression. Jan e04

Allen JD see Kung S

Allen MH, Feifel D, Lesem MD, Zimbroff DL, Ross R, Munzar P, Spyker DA, Cassella JV. Efficacy and safety of loxapine for inhalation in the treatment of agitation in patients with schizophrenia: a randomized, double blind, placebo-controlled trial. Oct 1313–1321

Almås B see Steen NE

Alonso M see González-Pinto A

Alonso P see Labad J

Altamura AC see Glick ID

Altoè G see Moscardino U

Altshuler LL see Gitlin MJ; Suri R

Álvarez E see Portella MJ

Ameral VE see Tedeschini E

Amminger GP see Yung AR

Amoyal NA see Gould NF

Ancelin M-L see Chaudieu I

Andel R see Van Dorn RA

Anderson-Hunt M see Berk M

Andrade C. Odd odds [letter with reply]. Nov 1558–1559

Andreassen OA see Steen NE

Andreescu C, Glick RM, Emeremni CA, Houck PR, Mulsant BH. Acupuncture for the treatment of major depressive disorder: a randomized controlled trial. Aug 1129–1135

Angermeier T see Hummel J

Annunziato RA see Shemesh E

Annweiler C see Richard-Devantoy S

Ansell EB see Yen S

Anway SD see Karayal ON

Appleby L see Laursen TM

Aquino A see Suri R

Arango C see Nuevo R

Araya S see Usall J

Arbuckle M see Harding KJK

Archambeau OG, Elhai JD, Frueh BC. Definition of psychological trauma and threshold for functional impairment in PTSD [letter]. Mar 416–417

Ardèvol M see Diez-Quevedo C

Arenovich T see Agid O

Arnold LE see Axelson DA; Frazier TW

Artigas F see Portella MJ

Asarnow JR see Vitiello B

Ashih H see Desseilles M

Asnis GM see Fava M

Athanasiou MC, Dettling M, Cascorbi I, Mosyagin I, Salisbury BA, Pierz KA, Zou W, Whalen H, Malhotra AK, Lencz T, Gerson SL, Kane JM, Reed CR. Candidate gene analysis identifies a polymorphism in *HLA-DQB1* associated with clozapine-induced agranulocytosis. Apr 458–463

Athanasiou M see Khan A

Axelson DA, Birmaher B, Findling RL, Fristad MA, Kowatch RA, Youngstrom EA, Arnold LE, Goldstein BI, Goldstein TR, Chang KD, DelBello MP, Ryan ND, Diler RS. Concerns regarding the inclusion of temper dysregulation disorder with dysphoria in the *Diagnostic And Statistical Manual of Mental Disorders*, Fifth Edition [commentary]. Sept 1257–1262

Axelson DA see Frazier TW

Ayuso-Mateos JL see Nuevo R

Baca-Garcia E see Dervic K

Bader A see Wirz-Justice A

Baer L see Chen JA; Posternak MA

Baghai TC, Varallo-Bedarida G, Born C, Häfner S, Schüle C, Eser D, Rupprecht R, Bondy B, von Schacky C. Major depressive disorder is associated with cardiovascular risk factors and low omega-3 index. Sept 1242–1247

Bagley SC. Predicting suicide attempt risk: logistic regression requires large sample sizes [letter with reply]. Dec 1698

Bai YM, Lin C-C, Chen J-Y, Chen TT, Su T-P, Chou P. Association of weight gain and metabolic syndrome in patients taking clozapine: an 8-year cohort study. June 751–756

Bai YM, Lin C-C, Chen TT, Su T-P. Reply to Suzuki T: Metabolic syndrome in inpatients treated with clozapine [letter]. June 873–874

Bak M see Lataster J

Baker K see Yung AR

Baldessarini RJ. Suicidal risk during antidepressant treatment [letter with reply]. May 722

Baldessarini RJ see Salvatore P

Ball DE see Signorovitch J

Ballesteros J see Portella MJ

Baltuch GH see Cristancho P

Bandinelli S see Vogelzangs N

Barbee JG, Thompson TR, Jamhour NJ, Stewart JW, Conrad EJ, Reimherr FW, Thompson PM, Shelton RC. Double-blind placebo-controlled trial of lamotrigine as an antidepressant augmentation agent in treatment-refractory unipolar depression. Oct 1405–1412

Barbeito S see González-Pinto A

Barkhof F see Oudega ML

Barkley RA see Adler LA

Barrett EA see Steen NE

Barton D. Review of Bauer MS: *A Mind Apart: Poems of Melancholy, Madness, and Addiction*. Apr 570–571

Bastani B see Fava M

Batzar E see Karayal ON

Bauer M see Strech D

Beauchet O see Richard-Devantoy S

Beblo T see Terfehr K

Becker MA see Boaz TL; Van Dorn RA

Beekman ATF see Lamers F; Oudega ML; Vogelzangs N; Wiersma JE

Benedetti F see Wirz-Justice A

Ben-Hamadi R see Signorovitch J

Bentley KH see Iovieno N

Beresin EV see Sadhu JM

Berg JP see Steen NE

Berger G see Yung AR

Bergink V, Lambregtse-van den Berg MP, Koorengevel KM, Kupka R, Kushner SA. First-onset psychosis occurring in the postpartum period: a prospective cohort study. Nov 1531–1537

Bergmann A see Buerger K

Berk M, Munib A, Dean O, Malhi GS, Kohlmann K, Schapkaitz I, Jeavons S, Katz F, Anderson-Hunt M, Conus P, Hanna B, Otmar R, Ng F, Copolov DL, Bush AI. Qualitative methods in early-phase drug trials: broadening the scope of data and methods from an RCT of *N*-acetylcysteine in schizophrenia. July 909–913

Berk M see Stafford L

Berlin HA, Koran LM, Jenike MA, Shapira NA, Chaplin W, Pallanti S, Hollander E. Double-blind, placebo-controlled trial of topiramate augmentation in treatment-resistant obsessive-compulsive disorder. May 716–721

Berman RM see Weisler RH

Berthele A see Hamann J

Bhagwagar Z see Saricicek A

Bhattaram A see Laughren TP

Bialobos S see Gerardin P

Biederman J, Fried R, Petty CR, Wozniak J, Doyle AE, Henin A, Corkum L, Claudat K, Faraone SV. Cognitive development in adults with attention-deficit/hyperactivity disorder: a controlled study in medication-naive adults across the adult life cycle. Jan 11–16

Biederman J see Hua LL

Biggs A see Cornwell BR

Birmaher B see Axelson DA; Frazier TW; Vitiello B

Birmes P see Chaudieu I

Birnbaum H see Signorovitch J

Bitter I see Volavka J
Bitzer J see Wirz-Justice A
Blacker D see Reiman EM
Blair SN see Trivedi MH
Blanco C see Comer JS; Pickering RP; Polo AJ
Blennow K see Buerger K
Bliziotes MM see Calarge CA
Blom JD see Daalman K
Blum JI see Lawson EA
Blumberg HP see Saricicek A
Boaz TL, Constantine RJ, Robst J, Becker MA, Howe AM. Risperidone long-acting therapy prescribing patterns and their impact on early discontinuation of treatment in a large Medicaid population. Aug 1079–1085
Boaz TL see Van Dorn RA
Bobo WV see Meltzer HY
Bodeau N see Gerardin P
Boelhouwer IG see Vogelzangs N
Bokde ALW see Frodl T
Boks MPM see Daalman K
Bonaccorso S see Meltzer HY
Bondy B see Baghai TC
Bonne O, Gill JM, Luckenbaugh DA, Collins C, Owens MJ, Alesci S, Neumeister A, Yuan P, Kinkead B, Manji HK, Charney DS, Vythilingam M. Corticotropin-releasing factor, interleukin-6, brain-derived neurotrophic factor, insulin-like growth factor-1, and substance P in the cerebrospinal fluid of civilians with posttraumatic stress disorder before and after treatment with paroxetine. Aug 1124–1128
Born C see Baghai TC
Bosch P see van den Noort M
Bourgeois JA, Seritan AL, Casillas EM, Hessl D, Schneider A, Yang Y, Kaur I, Cogswell JB, Nguyen DV, Hagerman RJ. Lifetime prevalence of mood and anxiety disorders in fragile X premutation carriers. Feb 175–182
Bowden CL see Brooks JO III
Bowers WA. Review of Safer DL, Telch CF, Chen EY: *Dialectical Behavior Therapy for Binge Eating and Bulimia*. Mar 421–422
Boyd RC, Joe S, Michalopoulos L, Davis E, Jackson JS. Prevalence of mood disorders and service use among US mothers by race and ethnicity: results from the National Survey of American Life. Nov 1538–1545
Bradley B, DeFife JA, Guarnaccia C, Phifer J, Fani N, Ressler KJ, Westen D. Emotion dysregulation and negative affect: association with psychiatric symptoms. May 685–691
Braga RJ see Gilbert AM
Brähler E see Timpano KR
Brandes M see Pollack MH
Brecht S, Desaiah D, Marechal ES, Santini AM, Podhorna J, Guelfi JD. Efficacy and safety of duloxetine 60 mg and 120 mg daily in patients hospitalized for severe depression: a double-blind randomized trial. Aug 1086–1094
Brent DA see Dervic K; Vitiello B
Britton A see Nabi H
Bromet EJ see Ruggero CJ
Brooks JO III, Goldberg JF, Ketter TA, Miklowitz DJ, Calabrese JR, Bowden CL, Thase ME. Safety and tolerability associated with second-generation antipsychotic polytherapy in bipolar disorder: findings from the Systematic Treatment Enhancement Program for Bipolar Disorder. Feb 240–247
Brower KJ, McCammon RJ, Wojnar M, Ilgen MA, Wojnar J, Valenstein M. Prescription sleeping pills, insomnia, and suicidality in the National Comorbidity Survey Replication. Apr 515–521
Brown FW. Review of Katon W, Maj M, Sartorius N (eds): *Depression and Diabetes*. Aug 1159–1160
Brückmann H see Frodl T
Bryant RA. Acute stress disorder as a predictor of posttraumatic stress disorder: a systematic review. Feb 233–239
Buckley PF see Kane JM
Buerger K, Uspenskaya O, Hartmann O, Hansson O, Minthon L, Blennow K, Moeller H-J, Teipel SJ, Ernst A, Bergmann A, Hampel H. Prediction of Alzheimer's disease using midregional proadrenomedullin and midregional proatrial natriuretic peptide: a retrospective analysis of 134 patients with mild cognitive impairment. Apr 556–563
Bühner M see Hamann J
Burdick KE see Gilbert AM
Bush AI see Berk M
Busschbach JJV see Soeteman DI
Bystritsky AM see Shiovitz TM; Stein MB
Calabrese JR, Prescott M, Tamburrino M, Liberzon I, Slembarski R, Goldmann E, Shirley E, Fine T, Goto T, Wilson K, Ganocy S, Chan P, Serrano MB, Sizemore J, Galea S. PTSD comorbidity and suicidal ideation associated with PTSD within the Ohio Army National Guard. Aug 1072–1078
Calabrese JR see Brooks JO III; Gao K; Kemp DE; Muzina DJ
Calarge CA, Ellingrod VL, Zimmerman B, Bliziotes MM, Schlechte JA. Variants of the serotonin transporter gene, selective serotonin reuptake inhibitors, and bone mass in risperidone-treated boys: a reanalysis of data from a cross-sectional study with emphasis on pharmacogenetics. Dec 1685–1690
Campbell EC see Caroff SN
Campbell-Sills L see Stein MB
Capello F see Moscardino U
Carballo JJ see Dervic K
Carlson BX see Weisler RH
Carlson GA see Ruggero CJ
Carmody TJ see Trivedi MH
Caroff SN, Davis VG, Miller DD, Davis SM, Rosenheck RA, McEvoy JP, Campbell EC, Saltz BL, Riggio S, Chakos MH, Swartz MS, Keefe RSE, Stroup TS, Lieberman JA, CATIE Investigators. Treatment outcomes of patients with tardive dyskinesia and chronic schizophrenia. Mar 295–303
Caroff SN see Gurrera RJ
Carpenter DJ, Fong R, Kraus JE, Davies JT, Moore C, Thase ME. Meta-analysis of efficacy and treatment-emergent suicidality in adults by psychiatric indication and age subgroup following initiation of paroxetine therapy: a complete set of randomized placebo-controlled trials. Nov 1503–1514
Carpenter DJ, Fong R, Kraus JE, Davies JT, Moore C, Thase ME. Reply to Andrade C: Odd odds [letter]. Nov 1559
Carroll BT see Gurrera RJ
Carson WH see Marcus RN
Carter T see Compton MT
Cascorbi I see Athanasiou MC
Casillas EM see Bourgeois JA
Cassella JV see Allen MH
Castellví P see Diez-Quevedo C
CATIE Investigators see Caroff SN
Cattaneo A see Mondelli V
Cavallo DA see Liu TC
Cerimele JM. Integrated medical care for patients with bipolar disorder: who will be the principal physician? [letter] May 723–724
Chakos MH see Caroff SN
Chan H-Y, Gau SS-F, Chang C-J. Reply to Peritogiannis V: Emerging role of atypical antipsychotics in the treatment of tardive dyskinesia induced by other atypical antipsychotics [letter]. July 1016–1017
Chan P see Calabrese JR
Chan PK see Muzina DJ
Chan RCK see Zhang W-F
Chandler K see Van Dorn RA
Chang C-J see Chan H-Y
Chang C-L see Kuo C-J
Chang KD see Axelson DA
Chang TE see Desseilles M
Chaplin W see Berlin HA
Chappell PB see Sachs GS
Charney DS see Bonne O; Murrough JW
Chatterji S see Nuevo R
Chaudieu I, Norton J, Ritchie K, Birmes P, Vaiva G, Ancelin M-L. Late-life health consequences of exposure to trauma in a general elderly population: the mediating role of reexperiencing posttraumatic symptoms. July 929–935
Chelminski I see Zimmerman M
Chen C-C see Kuo C-J
Chen C-N see Polo AJ
Chen JA, Papakostas GI, Youn SJ, Baer L, Clain AJ, Fava M, Mischoulon D. Association between patient beliefs regarding assigned treatment and clinical response: reanalysis of data from the *Hypericum* Depression Trial Study Group. Dec 1669–1676
Chen J-Y see Bai YM
Chen TT see Bai YM
Chen WJ see Kuo C-J
Chen Y see Meltzer HY
Chen Y-F see Khin NA
Chen Y-Y, Yip PSF. Suicide sex ratios after the inception of charcoal-burning suicide in Taiwan and Hong Kong [letter]. Apr 566–567
Cheng Q, Fu K-w, Yip PSF. Comparative study of online suicide-related information in Chinese and English. Mar 313–319
Chiles C. Review of Sadock BJ, Sadock VA: *Kaplan & Sadock's Pocket Handbook of Clinical Psychiatry, 5th ed*. Sept 1288–1289
Chou K-L, Liang K, Mackenzie CS. Binge drinking and Axis I psychiatric disorders in community-dwelling middle-aged and older adults: results from the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC). May 640–647

Chou K-L, Liang K, Sareen J. Association between social isolation and *DSM-IV* mood, anxiety, and substance use disorders: wave 2 of the National Epidemiologic Survey on Alcohol and Related Conditions. Nov 1468–1476
Chou K-L, Mackenzie CS, Liang K, Sareen J. Three-year incidence and predictors of first-onset of *DSM-IV* mood, anxiety, and substance use disorders in older adults: results from wave 2 of the National Epidemiologic Survey on Alcohol and Related Conditions. Feb 144–155
Chou P see Bai YM
Chou SP see Pickering RP
Church TS see Trivedi MH
Citrome L. Iloperidone: a clinical overview. Suppl 1, 19–23
Citrome L. Likelihood to be helped or harmed can assist in clinical decision-making [letter with reply]. Feb 261–262
Citrome L. Number needed to treat: what it is and what it isn't, and why every clinician should know how to calculate it [ASCP Corner]. Mar 412–413
Clain AJ see Chen JA
Clarke G see Vitiello B
Claudat K see Biederman J
Clayton PJ. Back to "normal bereavement" [letter with reply]. Feb 260
Cloutier G see Normand E
Cobo J see Usall J
Cogswell JB see Bourgeois JA
Cohen A see Gurrera RJ
Cohen D see Gerardin P
Cohen LJ see Katz C
Cohen LS see Suri R
Cohen R see Hamann J
Cohen-Mansfield J, Marx MS, Thein K, Dakheel-Ali M. Impact of stimuli on affect in persons with dementia. Apr 480–486
Collins C see Bonne O
Comer JS, Blanco C, Hasin DS, Liu S-M, Grant BF, Turner JB, Olfson M. Health-related quality of life across the anxiety disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC). Jan 43–50
Comijs HC see Lamers F; Oudega ML
Compton MT, Gordon TL, Goulding SM, Esterberg ML, Carter T, Leiner AS, Weiss PS, Druss BG, Walker EF, Kaslow NJ. Patient-level predictors and clinical correlates of duration of untreated psychosis among hospitalized first-episode patients. Feb 225–232
Compton MT, Gordon TL, Weiss PS, Walker EF. "Doses" of initial, untreated hallucinations and delusions: a proof-of-concept study of enhanced predictors of first-episode symptomatology and functioning relative to duration of untreated psychosis. Nov 1487–1493
Conrad EJ see Barbee JG
Conroy CM see Muzina DJ
Constantine RJ see Boaz TL
Conus P see Berk M
Conwell Y see Kuo C-J
Cooper J see Oude Voshaar RC
Copolov DL see Berk M
Corbin J-F see Normand E
Corkum L see Biederman J
Cornwell BR, Heller R, Biggs A, Pine DS, Grillon C. Becoming the center of attention in social anxiety disorder: startle reactivity to a virtual audience during speech anticipation. July 942–948
Correll CU. Addressing adverse effects of antipsychotic treatment in young patients with schizophrenia. Jan e01
Correll CU. Psychobiology and psychosocial functioning of schizoaffective disorder. Feb e05
Correll CU. Safety and tolerability of antipsychotic treatment in young patients with schizophrenia. Aug e26
Correll CU. What are we looking for in new antipsychotics? Suppl 1, 9–13
Correll CU, Kratochvil CJ, March JS. Developments in pediatric psychopharmacology: focus on stimulants, antidepressants, and antipsychotics. May 655–670
Correll CU, Lops JD, Figen V, Malhotra AK, Kane JM, Manu P. QT interval duration and dispersion in children and adolescents treated with ziprasidone. June 854–860
Correll CU see Glick ID; Kane JM; Manu P; Nielsen J
Corruble E, Falissard B, Gorwood P. Is *DSM-IV* bereavement exclusion for major depression relevant to treatment response? a case-control, prospective study. July 898–902
Corruble E, Falissard B, Gorwood P. Reply to Wakefield JC: Treatment outcome for bereavement-excluded depression: results of the study by Corruble et al are not what they seem [letter]. Aug 1155–1156
Corry NH see Gould NF
Corya S see Zanarini MC
Coryell WH see Leon AC
Costa J see Diez-Quevedo C
Cotter G see Shemesh E
Cox B see Pagura J
Craig TJ see Smith EG
Craske MG see Stein MB
Crawford C see Davidson JRT
Crisanti AS, Frueh C, Gundaya DM, Salvail FR, Triffleman EG. Ethnoracial disparities in sexual assault among Asian Americans and Native Hawaiians/other Pacific Islanders. June 820–826
Cristancho MA see Cristancho P
Cristancho P, Cristancho MA, Baltuch GH, Thase ME, O'Reardon JP. Effectiveness and safety of vagus nerve stimulation for severe treatment-resistant major depression in clinical practice after FDA approval: outcomes at 1 year. Oct 1376–1393
Croarkin PE see Wall CA
Cruz N, Vieta E. Antidepressants in acute bipolar depression: an inconclusive meta-analysis [letter with reply]. Mar 415–416
Csernansky JG see Glick ID
Culpepper L. Presentation and diagnosis of fibromyalgia. Dec e38
Culpepper L. Prevalence and impact of ADHD in college students. Sept e30
Culpepper L. Recognizing and diagnosing ADHD in college students. Oct e33
Culpepper L. Understanding the burden of depression. June e19
Cutler AJ see Khan A
Czobor P see Krakowski MI; Volavka J
Daalman K, Boks MPM, Diederen KMJ, de Weijer AD, Blom JD, Kahn RS, Sommer IEC. Same or different? a phenomenological comparison of auditory verbal hallucinations in healthy and psychotic individuals. Mar 320–325
Dakheel-Ali M see Cohen-Mansfield J
Dalrymple K see Zimmerman M
Damian M see Hausner L
Daniel DG see Kane JM
Darbois Y see Gerardin P
Davidson JRT, Crawford C, Ives JA, Jonas WB. Homeopathic treatments in psychiatry: a systematic review of randomized placebo-controlled studies. June 795–805
Davies JT see Carpenter DJ
Davis E see Boyd RC
Davis JM see Glick ID
Davis SM see Addington DE; Caroff SN
Davis VG see Caroff SN
Dawson DA see Pickering RP
Dazzan P see Mondelli V
Dean O see Berk M
DeBar L see Vitiello B
Deberdt W see Zanarini MC
de Craen AJM see Oudega ML
de Diego-Adeliño J see Portella MJ
DeFife JA see Bradley B
de Haan L see Lataster J
DelBello MP see Axelson DA
Delespaul PAEG see Lataster J
Delieu J see Lepping P
Delimon J see Soeteman DI
Demeter CA see Frazier TW
Derks EM see Volavka J
DeRoos F see Gurrera RJ
Dervic K, Carballo JJ, Baca-Garcia E, Galfalvy HC, Mann JJ, Brent DA, Oquendo MA. Moral or religious objections to suicide may protect against suicidal behavior in bipolar disorder. Oct 1390–1396
Desai RA see Liu TC
Desaiah D see Brecht S
Desmarais SL see Van Dorn RA
Desseilles M, Witte J, Chang TE, Iovieno N, Dording CM, Ashih H, Nyer M, Freeman MP, Fava M, Mischoulon D. Assessing the adequacy of past antidepressant trials: a clinician's guide to the antidepressant treatment response questionnaire [ASCP Corner]. Aug 1152–1154
Detke HC see Zanarini MC
Dettling M see Athanasiou MC
Deuschle M see Hummel J
de Weijer AD see Daalman K
Diago M see Diez-Quevedo C
Dickerson J see Vitiello B
Diederen KMJ see Daalman K
Diez-Quevedo C, Masnou H, Planas R, Castellví P, Giménez D, Morillas RM, Martín-Santos R, Navinés R, Solà R, Giner P, Ardèvol M, Costa J, Diago M, Pretel J. Prophylactic treatment with escitalopram of pegylated interferon alfa-2a–induced depression in hepatitis C: a 12-week, randomized, double-blind, placebo-controlled trial. Apr 522–528
Di Forti M see Mondelli V
Diler RS see Axelson DA
Dinh PV see Laughren TP

Dinstein Y see Nacasch N
Diplich D see Hamann J
Dodge KA. Review of Reynolds CR, Fletcher-Janzen E (eds): *Handbook of Clinical Child Neuropsychology, 3rd ed.* May 726
Dommergues M see Gerardin P
Donoho DA see Lawson EA
Dording CM see Desseilles M
do Rosário MC see Torres AR
Doshi JA see Olfson M
Doty L see George DT
Dowd SM see Wall CA
Doyle AE see Biederman J
Driessen M see Terfehr K
Druss BG see Compton MT; Pagura J
Dunlop BW see Rakofsky JJ
Dunn AL see Trivedi MH
Dunner DL. Review of Mrazek DA: *Psychiatric Pharmacogenomics.* May 727
Dupuy JM see Sachs GS
Earnest CP see Trivedi MH
Edelen MO see Yen S
Edlund MJ see Fortney JC
Eickhoff M see Gaebel W
Eikelenboom P see Oudega ML
Elhai JD see Archambeau OG
Elizagarate E see Lertxundi U
Ellingrod VL see Calarge CA
Elliott RL. Does combat trauma cause a majority of PTSD symptoms in combat veterans? [letter with reply] May 724–725
Ellis SP see Sublette ME
Ellison JM. Review of Depp CA, Jeste DV (eds): *Successful Cognition and Emotional Aging.* May 726–727
Emeremni CA see Andreescu C
Empana J-P see Nabi H
Emslie GJ see Vitiello B; Wall CA
Endicott J see Leon AC
Ernst A see Buerger K
Ernst E see Lee MS
Eronen M see Tchoukhine E
Eser D see Baghai TC
Esterberg ML see Compton MT
Eudicone JM see Weisler RH
EUFEST Study Group see Volavka J
Evans SJW see Petersen I
Evins AE see Iovieno N
Exner C see Timpano KR
Falissard B see Corruble E
Fan X, Liu EY, Hoffman VP, Potts AJ, Sharma B, Henderson DC. Triglyceride/high-density lipoprotein cholesterol ratio: a surrogate to predict insulin resistance and low-density lipoprotein cholesterol particle size in nondiabetic patients with schizophrenia. June 806–812
Fang Y see Gao K
Fani N see Bradley B
Faraone SV see Biederman J; Waxmonsky JG
Farber SB see Swardfager W
Farmer A see Uher R
Fauerbach JA see Gould NF
Fava GA see Grandi S
Fava M, Asnis GM, Shrivastava RK, Lydiard B, Bastani B, Sheehan DV, Roth T. Improved insomnia symptoms and sleep-related next-day functioning in patients with comorbid major depressive disorder and insomnia following concomitant zolpidem extended-release 12.5 mg and escitalopram treatment: a randomized controlled trial. July 914–928
Fava M, Schaefer K, Huang H, Wilson A, Iosifescu DV, Mischoulon D, Wessel TC. Post hoc analysis of the effect of nightly administration of eszopiclone and a selective serotonin reuptake inhibitor in patients with insomnia and anxious depression. Apr 473–479
Fava M, Shelton RC, Zajecka JM. Evidence for the use of L-methylfolate combined with antidepressants in MDD. Aug e25
Fava M see Chen JA; Desseilles M; Posternak MA; Tedeschini E; Zisook S
Fazel S see Jones RM
Feaganes JR see Shemesh E
Feifel D see Allen MH
Fein E see Gao K
Feingold A see Remington G
Fernando SC see Terfehr K
Ferrão YA see Torres AR
Ferrucci L see Vogelzangs N
Fiedorowicz JG see Leon AC
Figen V see Correll CU
Findling RL see Axelson DA; Frazier TW; Marcus RN
Fine T see Calabrese JR
First MB. Problematic *DSM-5* personality disorders proposal: options for plan B [commentary]. Oct 1341–1343
First MB see Wakefield JC
Fishman SM. Strategies for selecting treatment and mitigating risk in patients with chronic pain. Jan e02
Fleischhacker WW see Volavka J
Flood P see Rodriguez CI
Foa EB see Nacasch N
Fong R see Carpenter DJ
Fontenelle LF see Torres AR
Fortney JC, Pyne JM, Edlund MJ, Stecker T, Mittal D, Robinson DE, Henderson KL. Reasons for antidepressant nonadherence among veterans treated in primary care clinics. June 827–834
Fortney JC see Mittal D
Fossom L see Laughren TP
Foster JA see Lokuge S
Fostick L see Nacasch N
Foussias G see Agid O
Fraguas D see Nuevo R
Francey SM see Yung AR
Francis A see Gurrera RJ
Frasure-Smith N see Lespérance F
Frazier TW, Youngstrom EA, Horwitz SM, Demeter CA, Fristad MA, Arnold LE, Birmaher B, Kowatch RA, Axelson D, Ryan N, Gill MK, Findling RL. Relationship of persistent manic symptoms to the diagnosis of pediatric bipolar spectrum disorders. June 846–853
Freeman AM III. Review of Summers RF, Barger JP: *Psychodynamic Therapy: A Guide to Evidence-Based Practice.* July 1018–1019
Freeman BW. Review of Gutheil TG: *The Psychiatrist as Expert Witness, 2nd ed.* July 1019–1020
Freeman MP. Antidepressant medication treatment during pregnancy: prevalence of use, clinical implications, and alternatives. July 977–978
Freeman MP. Biopsychosocial vulnerabilities in women [introduction]. Nov 1529–1530
Freeman MP, Rapaport MH. Omega-3 fatty acids and depression: from cellular mechanisms to clinical care [ASCP Corner]. Feb 258–259
Freeman MP see Desseilles M; Gelenberg AJ
Freudenreich O see Goff DC
Frey BN see Kapczinski F; Lokuge S
Fried R see Biederman J
Friedman SH, Resnick PJ. Child murder and mental illness in parents: implications for psychiatrists [commentary]. May 587–588
Frisch U see Wirz-Justice A
Fristad MA see Axelson DA; Frazier TW
Frodl T, Scheuerecker J, Schoepf V, Linn J, Koutsouleris N, Bokde ALW, Hampel H, Möller H-J, Brückmann H, Wiesmann M, Meisenzahl E. Different effects of mirtazapine and venlafaxine on brain activation: an open randomized controlled fMRI study. Apr 448–457
Frölich L see Hausner L
Frucht S see Gurrera RJ
Frueh BC see Archambeau OG
Frueh C see Crisanti AS
Frye MA, Ha K, Kanba S, Kato T, McElroy SL, Özerdem A, Vázquez G, Vieta E. International Consensus Group on Depression Prevention in Bipolar Disorder [commentary]. Oct 1295–1310
Fu K-w see Cheng Q
Fujita H see Watanabe N
Furukawa TA see Watanabe N
Gaebel W, Riesbeck M, Wölwer W, Klimke A, Eickhoff M, von Wilmsdorff M, Lemke M, Heuser I, Maier W, Huff W, Schmitt A, Sauer H, Riedel M, Klingberg S, Köpcke W, Ohmann C, Möller H-J, German Study Group on First-Episode Schizophrenia. Relapse prevention in first-episode schizophrenia—maintenance vs intermittent drug treatment with prodrome-based early intervention: results of a randomized controlled trial within the German Research Network on Schizophrenia. Feb 205–218
Gaebel W, Riesbeck M. Reply to Suzuki T: Risks of intermittent antipsychotic treatment in schizophrenia [letter]. Jan 114–115
Galea S see Calabrese JR
Galfalvy HC see Dervic K
Galin A see Gerardin P
Gallego JA, Robinson DG, Sevy SM, Napolitano B, McCormack J, Lesser ML, Kane JM. Time to treatment response in first-episode schizophrenia: should acute treatment trials last several months? Dec 1691–1696
Gallipoli S see Khan A
Galper DI see Trivedi MH
Galynker II see Katz C
Ganocy SJ see Calabrese JR, Gao K, Muzina DJ
Ganoczy D see Smith EG
Gao K, Kemp DE, Calabrese JR. Reply to Citrome L: Likelihood to be helped or harmed can assist in clinical decision-making [letter]. Feb 262

Gao K, Kemp DE, Fein E, Wang Z, Fang Y, Ganocy SJ, Calabrese JR. Number needed to treat to harm for discontinuation due to adverse events in the treatment of bipolar depression, major depressive disorder, and generalized anxiety disorder with atypical antipsychotics. Aug 1063–1071
Gao K see Muzina DJ
Garno JL see Gilbert AM
Garré J-B see Richard-Devantoy S
Gau SS-F see Chan H-Y
Gaumond I see Normand E
Gaynes BN see Trivedi MH
Geant AL see Sublette ME
Gelenberg AJ, Freeman MP. Our sincere thanks [editorial]. Jan 6–10
George DT, Phillips MJ, Lifshitz M, Lionetti TA, Spero DE, Ghassemzedeh N, Doty L, Umhau JC, Rawlings RR. Fluoxetine treatment of alcoholic perpetrators of domestic violence: a 12-week, double-blind, randomized, placebo-controlled intervention study. Jan 60–65
Gerardin P, Wendland J, Bodeau N, Galin A, Bialobos S, Tordjman S, Mazet P, Darbois Y, Nizard J, Dommergues M, Cohen D. Depression during pregnancy: is the developmental impact earlier in boys? a prospective case-control study. Mar 378–387
German Study Group on First-Episode Schizophrenia see Gaebel W
Gerretsen P, Pollock BG. Rediscovering adverse anticholinergic effects [ASCP Corner]. June 869–870
Gerson SL see Athanasiou MC
Ghaemi SN. Reply to Rasmussen KG: Do antidepressants really beget more depressive episodes? [letter] Jan 116
Ghassemzedeh N see George DT
Gibbons RD see Woo J-M
Gilbert AM, Braga RJ, Burdick KE. Reply to Bagley SC: Predicting suicide attempt risk: logistic regression requires large sample sizes [letter]. Dec 1698
Gilbert AM, Garno JL, Braga RJ, Shaya Y, Goldberg TE, Malhotra AK, Burdick KE. Clinical and cognitive correlates of suicide attempts in bipolar disorder: is suicide predictable? Aug 1027–1033. Correction, Dec 1698
Gilbert RE see Petersen I
Gilbertson MW, Pitman RK. Reply to Elliott RL: Does combat trauma cause a majority of PTSD symptoms in combat veterans? [letter] May 725
Gill JM see Bonne O
Gill MK see Frazier TW
Gilles M see Hummel J
Gillihan SJ, Parens E. Should we expect "neural signatures" for *DSM* diagnoses? Oct 1383–1389
Giménez D see Diez-Quevedo C
Giner P see Diez-Quevedo C
Gitlin MJ, Mintz J, Sokolski K, Hammen C, Altshuler LL. Subsyndromal depressive symptoms after symptomatic recovery from mania are associated with delayed functional recovery. May 692–697
Glaesmer H see Timpano KR
Glatt SJ see Waxmonsky JG
Glick ID, Correll CU, Altamura AC, Marder SR, Csernansky JG, Weiden PJ, Leucht S, Davis JM. Mid-term and long-term efficacy and effectiveness of antipsychotic medications for schizophrenia: a data-driven, personalized clinical approach. Dec 1616–1627
Glick RM see Andreescu C
Gobburu J see Laughren TP
Goff DC, Hill M, Freudenreich O. Treatment adherence in schizophrenia and schizoaffective disorder. Apr e13
Goldberg JF. Antidepressant use and risk for suicide attempts in bipolar disorder [letter with reply]. Dec 1697
Goldberg JF see Brooks JO III
Goldberg TE see Gilbert AM
Goldblatt MJ. In memory of Jonathon O. Cole [letter]. June 874
Goldman D see Roy A
Goldmann E see Calabrese JR
Goldstein BI see Axelson DA
Goldstein MZ. Review of Fletcher-Janzen E: *The Neuropsychology of Women.* Feb 264–265
Goldstein RB see Pickering RP
Goldstein TR see Axelson DA
Golinelli D see Stein MB
Gollan JK see Trivedi MH
González DA see Ruggero CJ
González-Pinto A, Barbeito S, Alonso M, Alberich S, Haidar MK, Vieta E, Tabarés-Seisdedos R, Zorrilla I, González-Pinto MA, López P. Poor long-term prognosis in mixed bipolar patients: 10-year outcomes in the Vitoria Prospective Naturalistic Study in Spain. May 671–676
González-Pinto MA see González-Pinto A
Gordon TL see Compton MT
Gorwood P see Corruble E
Goto T see Calabrese JR
Gould NF, McKibben JB, Hall R, Corry NH, Amoyal NA, Mason ST, McCann UD, Fauerbach JA. Peritraumatic heart rate and posttraumatic stress disorder in patients with severe burns. Apr 539–547
Goulding SM see Compton MT
Grandi S, Sirri L, Tossani E, Fava GA. Psychological characterization of demoralization in the setting of heart transplantation. May 648–654
Grann M see Jones RM
Grannemann BD see Trivedi MH
Grant BF see Comer JS; Pickering RP
Greenhill LL see Hong HJ
Greer TL see Trivedi MH
Greil W see Stübner S
Greist JH. Review of Marks IM, Cavanagh K, Gega L: *Hands-On Help: Computer-Aided Psychotherapy.* June 876–877
Grillon C see Cornwell BR
Grilo CM see Yen S
Grohmann R see Stübner S
Gründer G see Paulzen M
Guarnaccia C see Bradley B
Guelfi JD see Brecht S
Gundaya DM see Crisanti AS
Gunderson JG see Yen S
Gupta S see Gurrera RJ
Gurrera RJ, Caroff SN, Cohen A, Carroll BT, DeRoos F, Francis A, Frucht S, Gupta S, Levenson JL, Mahmood A, Mann SC, Policastro MA, Rosebush PI, Rosenberg H, Sachdev PS, Trollor JN, Velamoor VR, Watson CB, Wilkinson JR. International consensus study of neuroleptic malignant syndrome diagnostic criteria using the Delphi method. Sept 1222–1228
Gurtovaya O see Sachs GS
Ha K see Frye MA
Häfner S see Baghai TC
Hagerman RJ see Bourgeois JA
Haidar MK see González-Pinto A
Hakko H see Tchoukhine E
Hall R see Gould NF
Hamann J, Mendel R, Reiter S, Cohen R, Bühner M, Schebitz M, Diplich D, Kissling W, Berthele A. Why do some patients with schizophrenia want to be engaged in medical decision making and others do not? Dec 1636–1643
Hammen C see Gitlin MJ
Hampel H see Buerger K; Frodl T
Handley R see Mondelli V
Hanna B see Berk M
Hansson O see Buerger K
Harding KJK, Rush AJ, Arbuckle M, Trivedi MH, Pincus HA. Measurement-based care in psychiatric practice: a policy framework for implementation. Aug 1136–1143
Harkavy-Friedman JM see Hong HJ
Hartmann O see Buerger K
Hasin DS see Comer JS; Pickering RP
Hausner L, Damian M, Sartorius A, Frölich L. Efficacy and cognitive side effects of electroconvulsive therapy (ECT) in depressed elderly inpatients with coexisting mild cognitive impairment or dementia. Jan 91–97
Heckers S. Review of Freedman R: *The Madness Within Us: Schizophrenia as a Neuronal Process.* July 1020
Hellemann G see Suri R
Heller R see Cornwell BR
Hellqvist Å see Weisler RH
Helsel JC see Sit D
Henderson DC see Fan X
Henderson KL see Fortney JC
Henigsberg N see Uher R
Henin A see Biederman J
Henley SS see Trivedi MH
Hepgul N see Mondelli V
Hernandez R see Lertxundi U
Herrmann N see Swardfager W
Herzog DB see Lawson EA
Hessl D see Bourgeois JA
Heuser I see Gaebel W
Hibbeln JR see Lewis MD
Hill M see Goff DC
Hirschfeld RMA. Review of Ketter TA (ed): *Handbook of Diagnosis and Treatment of Bipolar Disorders.* June 875–876
Hoffman VP see Fan X
Hoge EA see Pollack MH
Hollander E see Berlin HA
Hong HJ, Kim YS, Jon D-I, Soek JH, Hong N, Harkavy-Friedman JM, Miller AM, Greenhill LL. Mental health and extracurricular education in Korean first graders: a school-based cross-sectional study. June 861–868
Hong N see Hong HJ

Hope S see Steen NE
Hopwood CJ see Yen S
Horwitz SM see Frazier TW
Hösli I see Wirz-Justice A
Houck PR see Andreescu C
Howe AM see Boaz TL; Van Dorn RA
Hua LL, Wilens TE, Martelon M, Wong P, Wozniak J, Biederman J. Psychosocial functioning, familiality, and psychiatric comorbidity in bipolar youth with and without psychotic features. Mar 397–405
Huang B see Pickering RP
Huang H see Fava M
Hudson PR see Lepping P
Huerta-Ramos E see Usall J
Huff W see Gaebel W
Hummel J, Westphal S, Weber-Hamann B, Gilles M, Lederbogen F, Angermeier T, Luley C, Deuschle M, Kopf D. Serum lipoproteins improve after successful pharmacologic antidepressant treatment: a randomized open-label prospective trial. July 885–891
Hung HMJ see Laughren TP
Hunt JI see Topor DR
Hunter-Lavin C see Lepping P
Huppert JD see Nacasch N
Husain MM see Trivedi MH; Wall CA
Hyun DY see Lewis MD
Ice KS see Sachs GS
Ilgen MA see Brower KJ
Iniesta R see Usall J
Iosifescu DV see Fava M
Iovieno N, Tedeschini E, Bentley KH, Evins AE, Papakostas GI. Antidepressants for major depressive disorder and dysthymic disorder in patients with comorbid alcohol use disorders: a meta-analysis of placebo-controlled randomized trials. Aug 1144–1151
Iovieno N see Desseilles M; Tedeschini E
Ives JA see Davidson JRT
Iyengar S see Vitiello B
Jackson JS see Boyd RC
Jamhour NJ see Barbee JG
Janicak PG see Wall CA
Jayathilake K see Meltzer HY
Jazbec S see Wirz-Justice A
Jeavons S see Berk M
Jenike MA see Berlin HA
Joe S see Boyd RC
Joffe G see Tchoukhine E
Johnson E see Kemp DE
Johnson JE see Lewis MD
Jon D-I see Hong HJ
Jonas WB see Davidson JRT
Jones RM, Lichtenstein P, Grann M, Långström N, Fazel S. Alcohol use disorders in schizophrenia: a national cohort study of 12,653 patients. June 775–779
Joseph DI. Review of Clarkin JF, Fonagy P, Gabbard GO (eds): *Psychodynamic Psychotherapy for Personality Disorders: A Clinical Handbook*. Nov 1561–1562
Kahn RS see Daalman K; Volavka J
Kajdasz DK see Khan A
Kallenberg G see Zisook S
Kamen L see Marcus RN
Kanba S see Frye MA
Kane JM. Addressing side effects from antipsychotic treatment in schizophrenia. Feb e07
Kane JM. Improving treatment adherence in patients with schizophrenia. Sept e28
Kane JM. Lurasidone: a clinical overview. Suppl 1, 24–28
Kane JM. Performance improvement CME: schizoaffective disorder. July e23
Kane JM. Recent advances in treatments for schizophrenia [introduction]. Suppl 1, 3
Kane JM. Transitioning from acute to long-term treatment in schizophrenia. Mar e10
Kane JM, Correll CU. Performance improvement CME: managing schizophrenia. Oct e31
Kane JM, Mackle M, Snow-Adami L, Zhao J, Szegedi A, Panagides J. Randomized placebo-controlled trial of asenapine for the prevention of relapse of schizophrenia after long-term treatment. Mar 349–355
Kane JM, Potkin SG, Daniel DG, Buckley PF. Double-blind, randomized study comparing the efficacy and safety of sertindole and risperidone in patients with treatment-resistant schizophrenia. Feb 194–204
Kane JM see Athanasiou MC; Correll CU; Gallego JA; Manu P
Kapczinski F, Frey BN, Vieta E. Sleep and circadian rhythm disturbances in bipolar disorder: an urgent need for objective assessment and systematic follow-up [letter]. May 724–725
Kapur N see Oude Voshaar RC
Kapur S see Agid O; Remington G; Sparshatt A
Karayal ON, Anway SD, Batzar E, Vanderburg DG. Assessments of suicidality in double-blind, placebo-controlled trials of ziprasidone. Mar 367–375
Kaslow NJ see Compton MT
Kasuba B see Sachs GS
Kato T see Frye MA
Katsuki F see Watanabe N
Katz C, Yaseen ZS, Mojtabai R, Cohen LJ, Galynker II. Panic as an independent risk factor for suicide attempt in depressive illness: findings from the National Epidemiological Survey on Alcohol and Related Conditions (NESARC). Dec 1628–1635
Katz F see Berk M
Katz LY see Pagura J
Kaur I see Bourgeois JA
Kawamura C see Watanabe N
Keefe RSE see Caroff SN
Kegeles LS see Rodriguez CI
Keller MB see Leon AC; Vitiello B
Kelley D see Signorovitch J
Kelly D see Yung AR
Kemp DE, Johnson E, Wang WV, Tohen M, Calabrese JR. Clinical utility of early improvement to predict response or remission in acute mania: focus on olanzapine and risperidone. Sept 1236–1241
Kemp DE see Gao K; Muzina DJ
Kennard B see Vitiello B
Keshaviah A see Timpano KR
Ketter TA. Strategies for the early recognition of bipolar disorder. July e22
Ketter TA see Brooks JO III
Khalife S see Muzina DJ
Khalsa H-MK see Salvatore P
Khan A, Cutler AJ, Kajdasz DK, Gallipoli S, Athanasiou M, Robinson DS, Whalen H, Reed CR. Randomized, double-blind, placebo-controlled, 8-week study of vilazodone, a serotonergic agent for the treatment of major depressive disorder. Apr 441–447
Khan A see Weisler RH
Khan BK see Woolley JD
Khin NA, Chen Y-F, Yang Y, Yang P, Laughren TP. Exploratory analyses of efficacy data from major depressive disorder trials submitted to the US Food and Drug Administration in support of new drug applications. Apr 464–472. Correction, June 874
Khin NA, Chen Y-F, Yang Y, Yang P, Laughren TP. Reply to Shiovitz TM: Failure rate and "professional subjects" in clinical trials of major depressive disorder [letter]. Sept 1284–1285
Kidolezi Y see Signorovitch J
Kim JB see Woo J-M
Kim J-I see Lee MS
Kim JJ see Soeteman DI
Kim NS see Rottman BM
Kim YS see Hong HJ
King P. Bipolar disorder self-assessment. May e16
King P. 2011 ICBD conference coverage: practical applications of new research in bipolar disorder. Nov e34
Kinkead B see Bonne O
Kinley DJ, Walker JR, Mackenzie CS, Sareen J. Panic attacks and panic disorder in a population-based sample of active Canadian military personnel. Jan 66–74
Kirner-Veselinovic A see Paulzen M
Kirshner HS. Review of Hurley RA, Taber KH (eds): *Windows to the Brain: Insights From Neuroimaging*. Jan 117
Kiss A see Swardfager W
Kissling W see Hamann J
Kivimäki M see Nabi H
Kleban M. Review of Grant JE, Potenza MN (eds): *Young Adult Mental Health*. June 875
Klibanski A see Lawson EA
Klimek V see Laughren TP
Klimke A see Gaebel W
Klingberg S see Gaebel W
Klöppel S see van Elst LT
Kohlmann K see Berk M
Komarow H see Woo J-M
Kontos N. Review of Ghaemi SN: *The Rise and Fall of the Biopsychosocial Model: Reconciling Art and Science in Psychiatry*. Sept 1287–1288
Koorengevel KM see Bergink V
Köpcke W see Gaebel W
Kopf D see Hummel J
Koran LM see Berlin HA
Kotov R see Ruggero CJ
Koutsouleris N see Frodl T
Kowatch RA see Axelson DA; Frazier TW
Kozel FA see Wall CA
Kraemer HC. Another point of view: superiority, noninferiority, and the role of active comparators [commentary]. Oct 1350–1352
Kratochvil CJ see Correll CU

Kraus JE see Carpenter DJ
Krishnan-Sarin S see Liu TC
Kroenke K see Löwe B
Krogh J, Nordentoft M, Sterne JAC, Lawlor DA. Effect of exercise in clinically depressed adults: systematic review and meta-analysis of randomized controlled trials. Apr 529–538
Kryzhanovskaya L see Zanarini MC
Kung S, Allen JD. Patients and clinicians report higher-than-average satisfaction with psychiatric genotyping for depressed inpatients [letter]. Feb 262–263
Kuo C-J, Tsai S-Y, Liao Y-T, Conwell Y, Lin S-K, Chang C-L, Chen C-C, Chen WJ. Risk and protective factors for suicide among patients with methamphetamine dependence: a nested case-control study. Apr 487–493
Kupka R see Bergink V
Kurian BT see Trivedi MH
Kushner SA see Bergink V
Labad J, Alonso P, Segalàs C, Real E, Menchón JM. Reproductive hormone sensitivity and obsessive-compulsive disorder: are there differences in the genetic predisposition between symptom dimensions? [letter] Mar 417–418
Lambregtse-van den Berg MP see Bergink V
Lamers F, van Oppen P, Comijs HC, Smit JH, Spinhoven P, van Balkom AJLM, Nolen WA, Zitman FG, Beekman ATF, Penninx BWJH. Comorbidity patterns of anxiety and depressive disorders in a large cohort study: the Netherlands Study of Depression and Anxiety (NESDA). Mar 341–348
Lanctôt KL see Swardfager W
Lang AJ see Stein MB
Långström N see Jones RM
Lardinois M see Lataster J
Larsson S see Steen NE
Lataster J, van Os J, de Haan L, Thewissen V, Bak M, Lataster T, Lardinois M, Delespaul PAEG, Myin-Germeys I. Emotional experience and estimates of D_2 receptor occupancy in psychotic patients treated with haloperidol, risperidone, or olanzapine: an experience sampling study. Oct 1397–1404
Lataster T see Lataster J
Laughren TP, Gobburu J, Temple RJ, Unger EF, Bhattaram A, Dinh PV, Fossom L, Hung HMJ, Klimek V, Lee JE, Levin RL, Lindberg CY, Mathis M, Rosloff BN, Wang S-J, Wang Y, Yang P, Yu B, Zhang H, Zhang L, Zineh I. Vilazodone: clinical basis for the US Food and Drug Administration's approval of a new antidepressant. Sept 1166–1173
Laughren TP see Khin NA
Laursen TM, Munk-Olsen T, Mortensen PB, Abel KM, Appleby L, Webb RT. Filicide in offspring of parents with severe psychiatric disorders: a population-based cohort study of child homicide. May 698–703
Lawlor DA see Krogh J
Lawson A see Signorovitch J
Lawson EA, Donoho DA, Blum JI, Meenaghan EM, Misra M, Herzog DB, Sluss PM, Miller KK, Klibanski A. Decreased nocturnal oxytocin levels in anorexia nervosa are associated with low bone mineral density and fat mass. Nov 1546–1551
Layton ME. Review of Roll JM, Rawson RA, Ling W, Shoptaw S (eds): *Methamphetamine Addiction: From Basic Science to Treatment*. Mar 420
Lebowitz B see Zisook S
Lederbogen F see Hummel J
Lee JE see Laughren TP
Lee MS, Kim J-I, Ernst E. Massage therapy for children with autism spectrum disorders: a systematic review. Mar 406–411
Le Gall D see Richard-Devantoy S
Leiner AS see Compton MT
Lemke M see Gaebel W
Lencz T see Athanasiou MC
Leon AC. Comparative effectiveness clinical trials in psychiatry: superiority, noninferiority, and the role of active comparators. Oct 1344–1349
Leon AC. Evolution of psychopharmacology trial design and analysis: six decades in the making. Mar 331–340
Leon AC. Reply to Siris SG: Searching for serendipity [letter]. Aug 1157
Leon AC. Two clinical trial designs to examine personalized treatments for psychiatric disorders [commentary]. May 593–597
Leon AC, Solomon DA, Li C, Fiedorowicz JG, Coryell WH, Endicott J. Reply to Goldberg JF: Antidepressant use and risk for suicide attempts in bipolar disorder [letter]. Dec 1697
Leon AC, Solomon DA, Li C, Fiedorowicz JG, Coryell WH, Endicott J, Keller MB. Antidepressants and risks of suicide and suicide attempts: a 27-year observational study. May 580–586
Leon AC see Nierenberg AA
Lepping P, Delieu J, Mellor R, Williams JHH, Hudson PR, Hunter-Lavin C. Antipsychotic medication and oxidative cell stress: a systematic review. Mar 273–285
Lerner V see Ritsner MS
Lertxundi U, Sanchez P, Hernandez R, Elizagarate E. Case of agranulocytosis secondary to rechallenge with clozapine following severe neutropenia during previous therapy [Case Report]. Dec 1659
Lesem MD see Allen MH
Lespérance F, Frasure-Smith N, St-André E, Turecki G, Lespérance P, Wisniewski SR. Efficacy of omega-3 supplementation for major depression: a randomized controlled trial. Aug 1054–1062
Lespérance P see Lespérance F
Lesser IM see Zisook S
Lesser ML see Gallego JA
Leucht S see Glick ID
Levenson JL see Gurrera RJ
Levin RL see Laughren TP
Levkovitz Y, Tedeschini E, Papakostas GI. Efficacy of antidepressants for dysthymia: a meta-analysis of placebo-controlled randomized trials. Apr 509–514
Levkovitz Y see Tedeschini E
Lewis MD, Hibbeln JR, Johnson JE, Lin YH, Hyun DY, Loewke JD. Suicide deaths of active-duty US military and omega-3 fatty-acid status: a case-control comparison. Dec 1585–1590
Li C see Leon AC
Liang K see Chou K-L
Liao Y-T see Kuo C-J
Liberzon I see Calabrese JR
Libiger J see Volavka J
Lichtenstein P see Jones RM
Lieberman JA see Addington DE; Caroff SN
Lifshitz M see George DT
Liguori GM see Topor DR
Lin C-C see Bai YM
Lin D see Zanarini MC
Lin S-K see Kuo C-J
Lin YH see Lewis MD
Lindberg CY see Laughren TP
Linn J see Frodl T
Lionetti TA see George DT
Liu EY see Fan X
Liu S-M see Comer JS
Liu TC, Desai RA, Krishnan-Sarin S, Cavallo DA, Potenza MN. Problematic Internet use and health in adolescents: data from a high school survey in Connecticut. June 836–845
Loewke JD see Lewis MD
Lokuge S, Frey BN, Foster JA, Soares CN, Steiner M. Depression in women: windows of vulnerability and new insights into the link between estrogen and serotonin [commentary]. Nov e1563–e1569
Lomax JW. Review of Young-Bruehl E, Dunbar C: *One Hundred Years of Psychoanalysis, a Timeline: 1900–2000*. Apr 571
López P see González-Pinto A
Lops JD see Correll CU
Lorberg B see Saricicek A
Lorentzen S see Steen NE
Løvås K see Steen NE
Löwe B, Kroenke K, Spitzer RL, Williams JBW, Mussell M, Rose M, Wingenfeld K, Sauer N, Spitzer C. Trauma exposure and posttraumatic stress disorder in primary care patients: cross-sectional criterion standard study. Mar 304–312
Löwe B see Terfehr K
Lowenhaupt EA see Topor DR
Luckenbaugh DA see Bonne O
Luley C see Hummel J
Luther JF see Sit D; Trivedi MH; Zisook S
Lydiard B see Fava M
Lynch F see Vitiello B
Lynn DJ. Review of Starcevic V: *Anxiety Disorders in Adults: A Clinical Guide, 2nd ed*. Sept 1286–1287
Mackenzie CS see Chou K-L; Kinley DJ
Mackle M see Kane JM
MacQueen GM see Sidor MM
Maercker A see Schnyder U
Maggini C see Salvatore P
Mahmood A see Gurrera RJ
Maier W see Gaebel W
Makhinson M, Tsuang J. Review of Alanen YO, de Chavez MG, Silver A-LS, Martindale B (eds): *Psychotherapeutic Approaches to Schizophrenic Psychoses: Past, Present, and Future*. Apr 570
Malhi GS see Berk M
Malhotra AK see Athanasiou MC; Correll CU; Gilbert AM
Maloney K see Saricicek A
Man S-L see Petersen I

Mancini C see Van Ameringen M
Manji HK see Bonne O
Mankoski R see Marcus RN
Mann JJ see Dervic K; Sublette ME; Woo J-M
Mann S see Remington G
Mann SC see Gurrera RJ
Manning JS. Selecting appropriate treatment for patients who are nonresponsive to initial therapy. Aug e27
Manos G see Marcus RN
Manu P, Kane JM, Correll CU. Sudden deaths in psychiatric patients. July 936–941
Manu P see Correll CU
Mar M see Ritsner MS
March JS see Correll CU
Marchand S see Normand E
Marcus RN, Owen R, Manos G, Mankoski R, Kamen L, McQuade RD, Carson WH, Findling RL. Safety and tolerability of aripiprazole for irritability in pediatric patients with autistic disorder: a 52-week, open-label, multicenter study. Sept 1270–1276
Marcus SC see Olfson M
Marder SR see Glick ID
Marechal ES see Brecht S
Markowitz JC see Yen S
Marmot MG see Nabi H
Martelon M see Hua LL
Martinez J see Zimmerman M
Martín-Santos R see Diez-Quevedo C
Marx MS see Cohen-Mansfield J
Marzolini S see Swardfager W
Masnou H see Diez-Quevedo C
Mason ST see Gould NF
Mathew SJ see Murrough JW
Mathis M see Laughren TP
Mayes TL see Vitiello B
Mazet P see Gerardin P
McCammon RJ see Brower KJ
McCann UD see Gould NF
McCormack J see Gallego JA
McCracken JT see Vitiello B
McElroy SL see Frye MA
McEvoy JP see Addington DE; Caroff SN
McGlashan TH see Yen S
McGorry PD see Yung AR
McGuffin P see Uher R
McIntyre RS. Implementing guideline-based strategies to avoid relapse and recurrence in depression. Nov e35
McIntyre RS. Long-term treatment of bipolar disorder in adults. Feb e06
McIntyre RS, Wagner KD. Performance improvement CME: long-term treatment of bipolar disorder. Mar e09
McKhann GM see Reiman EM
McKibben JB see Gould NF
McQuade RD see Marcus RN
Meenaghan EM see Lawson EA
Meerman AMMA see Soeteman DI
Meisenzahl E see Frodl T
Melle I see Steen NE
Mellor R see Lepping P
Meltzer HY, Bonaccorso S, Bobo WV, Chen Y, Jayathilake K. 12-Month randomized, open-label study of the metabolic effects of olanzapine and risperidone in psychotic patients: influence of valproic acid augmentation. Dec 1602–1610
Menchón JM see Labad J
Mendel R see Hamann J
Mendez MF. Pathological stealing in dementia: poor response to SSRI medications [letter]. Mar 418–419
Mendlewicz J see Uher R
Merlo LJ see Stone AM
Methlie P see Steen NE
Michalopoulos L see Boyd RC
Miguel EC see Torres AR
Miklowitz DJ see Brooks JO III
Milaneschi Y see Vogelzangs N
Miller AM see Hong HJ
Miller BL see Woolley JD
Miller DD see Caroff SN
Miller KK see Lawson EA
Minthon L see Buerger K
Mintz J see Gitlin MJ
Miodownik C see Ritsner MS
Miorelli A see Mondelli V
Mischoulon D. Impact of omega-3 fatty acids on depressive disorders and suicidality: can we reconcile 2 studies with seemingly contradictory results? [commentary] Dec 1574–1576
Mischoulon D see Chen JA; Desseilles M; Fava M
Misra M see Lawson EA
Mittal D, Fortney JC, Pyne JM, Wetherell JL. Predictors of persistence of comorbid generalized anxiety disorder among veterans with major depressive disorder. Nov 1445–1451
Mittal D see Fortney JC
Mohamed S see Addington DE
Mojtabai R see Katz C; Pagura J
Möller H-J see Buerger K; Frodl T; Gaebel W
Mondelli V, Cattaneo A, Murri MB, Di Forti M, Handley R, Hepgul N, Miorelli A, Navari S, Papadopoulos AS, Aitchison KJ, Morgan C, Murray RM, Dazzan P, Pariante CM. Stress and inflammation reduce brain-derived neurotrophic factor expression in first-episode psychosis: a pathway to smaller hippocampal volume. Dec 1677–1684
Moore C see Carpenter DJ
Moreira ALR see Van Meter AR
Morenz B. Review of Simon RI, Gold LH (eds): *The American Psychiatric Publishing Textbook of Forensic Psychiatry, 2nd ed.* Dec 1700
Morey LC see Yen S
Morgan C see Mondelli V
Morillas RM see Diez-Quevedo C
Mork E see Steen NE
Morokuma I see Watanabe N
Morris DW see Trivedi MH; Zisook S
Mors O see Uher R
Mortensen PB see Laursen TM
Moscardino U, Scrimin S, Capello F, Altoè G. Are Beslan's children learning to cope? a 3-year prospective study of youths exposed to terrorism. Sept 1277–1283
Moshier SJ see Pollack MH
Mosyagin I see Athanasiou MC
Muhtz C see Terfehr K
Müller J see Schnyder U
Mulsant BH see Andreescu C
Munib A see Berk M
Munk-Jørgensen P see Nielsen J
Munk-Olsen T see Laursen TM
Munzar P see Allen MH
Muralidharan A see Saricicek A
Murphy E see Oude Voshaar RC
Murray RM see Mondelli V
Murri MB see Mondelli V
Murrough JW, Perez AM, Mathew SJ, Charney DS. Case of sustained remission following an acute course of ketamine in treatment-resistant depression [letter]. Mar 414–415
Murthy NK see Woolley JD
Mussell M see Löwe B
Muzina DJ, Gao K, Kemp DE, Khalife S, Ganocy SJ, Chan PK, Serrano MB, Conroy CM, Calabrese JR. Acute efficacy of divalproex sodium versus placebo in mood stabilizer–naive bipolar I or II depression: a double-blind, randomized, placebo-controlled trial. June 813–819
Myin-Germeys I see Lataster J
Nabi H, Kivimäki M, Empana J-P, Sabia S, Britton A, Marmot MG, Shipley MJ, Singh-Manoux A. Combined effects of depressive symptoms and resting heart rate on mortality: the Whitehall II Prospective Cohort Study. Sept 1199–1206
Nacasch N, Foa EB, Huppert JD, Tzur D, Fostick L, Dinstein Y, Polliack M, Zohar J. Prolonged exposure therapy for combat- and terror-related posttraumatic stress disorder: a randomized control comparison with treatment as usual. Sept 1174–1180
Naidoo N see Nuevo R
Nakata A. Work hours, sleep sufficiency, and prevalence of depression among full-time employees: a community-based cross-sectional study. May 605–614
Napolitano B see Gallego JA
Navari S see Mondelli V
Navinés R see Diez-Quevedo C
Nazareth I see Petersen I
Neijber A see Weisler RH
Nelson B see Yung AR
Nelson JC see Tedeschini E
Neumeister A see Bonne O
Newcorn JH. Risks and benefits of available treatments for adult ADHD. Mar e12
Newcorn JH see Adler LA
Ng F see Berk M
Nguyen DV see Bourgeois JA
Nielsen J, Munk-Jørgensen P, Skadhede S, Correll CU. Determinants of poor dental care in patients with schizophrenia: a historical, prospective database study. Feb 140–143
Nierenberg AA. Alternatives to antidepressants in treating acute bipolar depression. Jan e03
Nierenberg AA. Reply to Teboul E: Keeping 'em honest: the current crisis of confidence in antidepressants [letter]. July 1015–1016
Nierenberg AA, Leon AC, Price LH, Shelton RC, Trivedi MH. Crisis of confidence: antidepressant risk versus benefit. Mar e11
Nierenberg AA, Leon AC, Price LH, Shelton RC, Trivedi MH. Current crisis of confidence in antidepressants [commentary]. Jan 27–33
Nierenberg AA see Peters AT; Posternak MA; Zisook S
Nizard J see Gerardin P
Noien WA see Lamers F; Weisler RH

Nomura K see Suzuki T
Nordentoft M see Krogh J
Normand E, Potvin S, Gaumond I, Cloutier G, Corbin J-F, Marchand S. Pain inhibition is deficient in chronic widespread pain but normal in major depressive disorder. Feb 219–224
Norton J see Chaudieu I
Nuevo R, Chatterji S, Fraguas D, Verdes E, Naidoo N, Arango C, Ayuso-Mateos JL. Increased risk of diabetes mellitus among persons with psychotic symptoms: results from the WHO World Health Survey. Dec 1592–1599
Nurnberg HG. Randomized controlled trials of olanzapine treatment of borderline personality disorder: two similar studies with different results [commentary]. Oct 1363–1365
Nutt DJ. Highlights of the International Consensus Statement on Major Depressive Disorder. June e21
Nyer M see Desseilles M
Ochoa S see Usall J
Oh PI see Swardfager W
Ohmann C see Gaebel W
Olfson M, Marcus SC, Doshi JA. Reply to van den Noort M: Schizophrenia-related outpatient treatment of Medicaid-financed patients after hospital discharge [letter]. Jan 113–114
Olfson M see Comer JS
Olié J-P see Richard-Devantoy S
Oller S see Portella MJ
Onorato M see Vitiello B
Oquendo MA see Dervic K
O'Reardon JP see Cristancho P
Otmar R see Berk M
Otte C see Terfehr K
Oude Voshaar RC, Cooper J, Murphy E, Steeg S, Kapur N, Purandare NB. First episode of self-harm in older age: a report from the 10-year prospective Manchester Self-Harm project. June 737–743
Oudega ML, van Exel E, Wattjes MP, Comijs HC, Scheltens P, Barkhof F, Eikelenboom P, de Craen AJM, Beekman ATF, Stek ML. White matter hyperintensities, medial temporal lobe atrophy, cortical atrophy, and response to electroconvulsive therapy in severely depressed elderly patients. Jan 104–112
Owen R see Marcus RN
Owens MJ see Bonne O
Özerdem A see Frye MA
Padrino SL. Review of Morgan C, Bhugra D (eds): *Principles of Social Psychiatry, 2nd ed.* Nov 1560–1561
Pagura J, Katz LY, Mojtabai R, Druss BG, Cox B, Sareen J. Antidepressant use in the absence of common mental disorders in the general population. Apr 494–501
Pallanti S see Berlin HA
Panagides J see Kane JM
PanYuen H see Yung AR
Papadopoulos AS see Mondelli V
Papakostas GI see Chen JA; Iovieno N; Levkovitz Y; Tedeschini E
Parens E see Gillihan SJ
Pariante CM see Mondelli V
Paris J. Dimensional diagnosis and *DSM-5* [commentary]. Oct 1340
Patel MX see Sparshatt A
Patkar AA see Paulozzi LJ
Patterson B see Van Ameringen M
Patwa HS see Volpe D
Paulozzi LJ, Weisler RH, Patkar AA. National epidemic of unintentional prescription opioid overdose deaths: how physicians can help control it [commentary]. May 589–592
Paulsson B see Weisler RH
Paulzen M, Tauber SC, Kirner-Veselinovic A, Gründer G. Cytochrome P450 2D6 polymorphism and its impact on decision-making in psychopharmacotherapy: finding the right way in an ultrarapid metabolizing patient [Case Report]. Nov 1465–1467
Peele R, Siddiqi H. Review of Blackman JS: *Get the Diagnosis Right: Assessment and Treatment Selection for Mental Disorders.* Sept 1287
Penninx BWJH see Lamers F; Vogelzangs N; Wiersma JE
Perel JM see Sit D
Perez AM see Murrough JW
Pérez V see Portella MJ
Peritogiannis V, Tsouli S. Emerging role of atypical antipsychotics in the treatment of tardive dyskinesia induced by other atypical antipsychotics [letter with reply]. July 1016
Perlis ML see Watanabe N
Peters AT, Nierenberg AA. Stepping back to step forward: lessons from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) [ASCP Corner]. Oct 1429–1431
Petersen I, Gilbert RE, Evans SJW, Man S-L, Nazareth I. Pregnancy as a major determinant for discontinuation of antidepressants: an analysis of data from The Health Improvement Network. July 979–985
Petersen RC see Reiman EM
Petrovic A see Uher R
Petti TA. Review of Whitaker R: *Anatomy of an Epidemic: Magic Bullets, Psychiatric Drugs, and the Astonishing Rise of Mental Illness in America.* Mar 421
Petty CR see Biederman J
Pfennig A see Strech D
Phifer J see Bradley B
Phillips G see Signorovitch J
Phillips LJ see Yung AR
Phillips MJ see George DT
Pickering RP, Goldstein RB, Hasin DS, Blanco C, Smith SM, Huang B, Pulay AJ, Ruan WJ, Saha TD, Stinson FS, Dawson DA, Chou SP, Grant BF. Temporal relationships between overweight and obesity and *DSM-IV* substance use, mood, and anxiety disorders: results from a prospective study, the National Epidemiologic Survey on Alcohol and Related Conditions. Nov 1494–1502
Pierz KA see Athanasiou MC
Pies R see Zisook S
Pikalov A see Weisler RH
Pincus HA see Harding KJK
Pine DS see Cornwell BR
Pintov L see Ritsner MS
Pitman RK see Gilbertson MW
Pittman B see Saricicek A
Planas R see Diez-Quevedo C
Podhorna J see Brecht S
Policastro MA see Gurrera RJ
Pollack MH, Hoge EA, Worthington JJ, Moshier SJ, Wechsler RS, Brandes M, Simon NM. Eszopiclone for the treatment of posttraumatic stress disorder and associated insomnia: a randomized, double-blind, placebo-controlled trial. July 892–897
Polliack M see Nacasch N
Pollock BG see Gerretsen P
Polo AJ, Alegría M, Chen C-N, Blanco C. Prevalence and comorbidity of social anxiety disorder among United States Latinos: a retrospective analysis of data from 2 national surveys. Aug 1096–1105
Porta G see Vitiello B
Portella MJ, Ballesteros J, Artigas F, Pérez V. Reply to Terao T: Can pindolol really enhance antidepressant effect? [letter] Nov 1558
Portella MJ, de Diego-Adeliño J, Ballesteros J, Puigdemont D, Oller S, Santos B, Álvarez E, Artigas F, Pérez V. Can we really accelerate and enhance the selective serotonin reuptake inhibitor antidepressant effect? a randomized clinical trial and a meta-analysis of pindolol in nonresistant depression. July 962–969
Posternak MA, Baer L, Nierenberg AA, Fava M. Response rates to fluoxetine in subjects who initially show no improvement. July 949–954
Postolache TT see Woo J-M
Potenza MN see Liu TC
Potkin SG. Asenapine: a clinical overview. Suppl 1, 14–18
Potkin SG see Kane JM
Potts AJ see Fan X
Potvin S see Normand E
Prakash R. Review of McKeon: *Suicidal Behavior.* Feb 264
Prescott M see Calabrese JR
Pretel J see Diez-Quevedo C
Price LH see Nierenberg AA
Puigdemont D see Portella MJ
Pulay AJ see Pickering RP
Purandare NB see Oude Voshaar RC
Putkonen H see Tchoukhine E
Pyne JM see Fortney JC; Mittal D
Qin P see Woo J-M
Raidma M see Tchoukhine E
Rajewska-Rager A see Uher R
Rakofsky JJ, Dunlop BW. Treating nonspecific anxiety and anxiety disorders in patients with bipolar disorder: a review. Jan 81–90
Ramos-Cerqueira ATA see Torres AR
Randall M. Review of Glassman A, Maj M, Sartorius N (eds): *Depression and Heart Disease.* Aug 1158–1159
Rankin KP see Woolley JD
Rapaport MH see Freeman MP
Räsänen P see Tchoukhine E
Rasmussen KG. Do antidepressants really beget more depressive episodes? [letter with reply] Jan 115–116

Ratner Y see Ritsner MS
Rauer S see van Elst LT
Rawlings RR see George DT
Real E see Labad J
Reed CR see Athanasiou MC; Khan A
Reiman EM, McKhann GM, Albert MS, Sperling RA, Petersen RC, Blacker D. Alzheimer's disease: implications of the updated diagnostic and research criteria. Sept 1190–1196
Reiman EM, McKhann GM, Albert MS, Sperling RA, Petersen RC, Blacker D. Clinical impact of updated diagnostic and research criteria for Alzheimer's disease. Dec e37
Reimherr FW see Barbee JG
Reiter S see Hamann J
Remington G, Seeman P, Feingold A, Mann S, Shammi C, Kapur S. "Extended" antipsychotic dosing in the maintenance treatment of schizophrenia: a double-blind, placebo-controlled trial. Aug 1042–1048
Remington G see Agid O
Resnick PJ see Friedman SH
Ressler KJ see Bradley B
Reynolds CF III see Zisook S
Richard-Devantoy S, Annweiler C, Le Gall D, Garré J-B, Olié J-P, Beauchet O. Cognitive inhibition in suicidal depressed elderly: a case-control pilot study [letter]. June 871–872
Riecher-Rössler A see Wirz-Justice A
Riedel M see Gaebel W
Rief W see Timpano KR
Riesbeck M see Gaebel W
Rietschel M see Uher R
Riggio S see Caroff SN
Rijnierse P see Soeteman DI
Ritchie K see Chaudieu I
Ritsner MS, Miodownik C, Ratner Y, Shleifer T, Mar M, Pintov L, Lerner V. L-theanine relieves positive, activation, and anxiety symptoms in patients with schizophrenia and schizoaffective disorder: an 8-week, randomized, double-blind, placebo-controlled, 2-center study. Jan 34–42
Roberts MW. Review of Kay J, Schwartz V (eds): *Mental Health Care in the College Community*. Nov 1560
Robinson DE see Fortney JC
Robinson DG see Gallego JA
Robinson DS see Khan A
Robst J see Boaz TL
Roca M see Usall J
Rodriguez CI, Kegeles LS, Flood P, Simpson HB. Rapid resolution of obsessions after an infusion of intravenous ketamine in a patient with treatment-resistant obsessive-compulsive disorder [letter]. Apr 567–569
Rofman ES. Review of Gask L, Lester H, Kendrick T, Peveler (eds): *Primary Care Mental Health*. July 1018
Rogers CA see Woo J-M
Rose M see Löwe B
Rose RD see Stein MB
Rosebush PI see Gurrera RJ
Rosenberg H see Gurrera RJ
Rosenheck RA see Addington DE; Caroff SN
Rosloff BN see Laughren TP
Ross ML see Yung AR
Ross R see Allen MH
Rossum BV see Soeteman DI
Roth T see Fava M; Surman CBH
Rottman BM, Kim NS, Ahn W-k, Sanislow CA. Can personality disorder experts recognize *DSM-IV* personality disorders from five-factor model descriptions of patient cases? May 630–639
Roy A, Roy M, Goldman D. Childhood trauma and depressive symptoms in type 1 diabetes. Aug 1049–1053
Roy M see Roy A
Roy-Byrne PP see Stein MB
Ruan WJ see Pickering RP
Rubinstein D see Shemesh E
Ruf B see Saricicek A
Ruggero CJ, Kotov R, Carlson GA, Tanenberg-Karant M, González DA, Bromet EJ. Diagnostic consistency of major depression with psychosis across 10 years. Sept 1207–1213
Rupprecht R see Baghai TC
Rush AJ see Harding KJK; Zisook S
Ryan ND see Axelson DA; Frazier TW; Vitiello B
Sabia S see Nabi H
Sachdev PS see Gurrera RJ
Sachs GS, Dupuy JM, Wittmann CW. Pharmacologic treatment of bipolar disorder. May 704–715
Sachs GS, Ice KS, Chappell PB, Schwartz JH, Gurtovaya O, Vanderburg DG, Kasuba B. Efficacy and safety of adjunctive oral ziprasidone for acute treatment of depression in patients with bipolar I disorder: a randomized, double-blind, placebo-controlled trial. Oct 1413–1422
Sadhu JM, Beresin EV. Review of Parens H: *Handling Children's Aggression Constructively: Toward Taming Human Destructiveness*. Oct 1432
Saha TD see Pickering RP
Sajeev G see Agid O
Saleem M see Swardfager W
Salisbury BA see Athanasiou MC
Salomon RM. Review of David AS, Fleminger S, Kopelman MD, Lovestone S, Mellers JDC: *Lishman's Organic Psychiatry, 4th ed.* Jan 118–119
Saltz BL see Caroff SN
Salvail FR see Crisanti AS
Salvatore P, Baldessarini RJ, Tohen M, Khalsa H-MK, Sanchez-Toledo JP, Zarate CA Jr, Vieta E, Maggini C. McLean-Harvard International First-Episode Project: two-year stability of *ICD-10* diagnoses in 500 first-episode psychotic disorder patients. Feb 183–193
Salzman C. Review of Hertzman M, Adler L: *Clinical Trials in Psychopharmacology: A Better Brain*. Apr 571
Sampson SM see Wall CA
Sanacora G see Saricicek A
Sanchez P see Lertxundi U
Sanchez-Toledo JP see Salvatore P
Sanislow CA see Rottman BM; Yen S
Santini AM see Brecht S
Santos B see Portella MJ
Santra M see Shemesh E
Sareen J see Chou K-L; Kinley DJ; Pagura J
Saricicek A, Maloney K, Muralidharan A, Ruf B, Blumberg HP, Sanacora G, Lorberg B, Pittman B, Bhagwagar Z. Levetiracetam in the management of bipolar depression: a randomized, double-blind, placebo-controlled trial. June 744–750
Sartorius A see Hausner L
Sasaki M see Watanabe N
Sauer H see Gaebel W
Sauer N see Löwe B
Schaefer K see Fava M
Schapkaitz I see Berk M
Schebitz M see Hamann J
Scheltens P see Oudega ML
Scheuerecker J see Frodl T
Schlechte JA see Calarge CA
Schlosser N see Terfehr K
Schmitt A see Gaebel W
Schneider A see Bourgeois JA
Schnyder U, Müller J, Maercker A, Wittmann L. Brief eclectic psychotherapy for PTSD: a randomized controlled trial [letter]. Apr 564–566
Schoepf V see Frodl T
Schooler NR. Jonathan O. Cole, MD (1925–2009): innovator in clinical psychopharmacology and of the ECDEU/NCDEU tradition. Mar 286–287
Schüle C see Baghai TC
Schulz SC see Zanarini MC
Schwartz JH see Sachs GS
Scrimin S see Moscardino U
Seeman P see Remington G
Segalàs C see Labad J
Seritan AL see Bourgeois JA
Serrano MB see Calabrese JR; Muzina DJ
Serrano-Blanco A see Usall J
Sevy SM see Gallego JA
Shammi C see Remington G
Shapira NA see Berlin HA
Sharma B see Fan X
Shaya Y see Gilbert AM
Shea MT see Yen S
Shear MK see Zisook S
Sheehan DV see Fava M
Shelton JS. Cosmetics count [Publisher's Note]. Sept 1165
Shelton JS. JCP 2011: our world keeps improving [Publisher's Note]. June 736
Shelton JS. NCDEU Festschrift—celebrating 50 years [Publisher's Note]. May 579
Shelton RC, Trivedi MH. Challenges and algorithm-guided treatment in major depressive disorder. Apr e14
Shelton RC, Trivedi MH. Moderators of antidepressant response in major depression. Oct e32
Shelton RC, Trivedi MH. Performance improvement CME: algorithms and EMRs in depression. Sept e29
Shelton RC, Trivedi MH. Using algorithms and computerized decision support systems to treat major depression. Dec e36
Shelton RC, Trivedi MH. Using moderator-based algorithms and electronic medical records to achieve optimal outcomes in depression. July e24
Shelton RC see Barbee JG; Fava M; Nierenberg AA
Shemesh E, Annunziato RA, Weatherley BD, Cotter G, Feaganes JR, Santra M, Yehuda R, Rubinstein D. Randomized controlled trial of the safety and promise of cognitive-behavioral therapy using imaginal exposure in patients with posttraumatic stress disorder resulting from cardiovascular illness. Feb 168–174

Sherbourne CD see Stein MB
Shimodera S see Watanabe N
Shiovitz AM see Shiovitz TM
Shiovitz TM, Zarrow ME, Shiovitz AM, Bystritsky AM. Failure rate and "professional subjects" in clinical trials of major depressive disorder [letter with reply]. Sept 1284
Shipley MJ see Nabi H
Shirley E see Calabrese JR
Shleifer T see Ritsner MS
Shore JH. Review of Stern TA, Fricchione GL, Cassem NH, Jellinek MS, Rosenbaum JF (eds): *Massachusetts General Hospital Handbook of General Hospital Psychiatry, 6th ed.* July 1019
Shrivastava RK see Fava M
Siddiqi H see Peele R
Sidor MM, MacQueen GM. Antidepressants for the acute treatment of bipolar depression: a systematic review and meta-analysis. Feb 156–167
Sidor MM, MacQueen GM. Reply to Cruz N, Vieta E: Antidepressants in acute bipolar depression: an inconclusive meta-analysis [letter]. Mar 416
Signorovitch J, Birnbaum H, Ben-Hamadi R, Yu AP, Kidolezi Y, Kelley D, Phillips G, Lawson A, Ball DE. Increased olanzapine discontinuation and health care resource utilization following a Medicaid policy change. June 787–794
Sim LA see Wall CA
Simmons MB see Yung AR
Simon NM see Pollack MH; Zisook S
Simpson HB see Rodriguez CI
Singh-Manoux A see Nabi H
Siris SG. Searching for serendipity [letter with reply]. Aug 1156–1157
Sirri L see Grandi S
Sit D, Perel JM, Wisniewski SR, Helsel JC, Luther JF, Wisner KL. Mother-infant antidepressant concentrations, maternal depression, and perinatal events. July 994–1001
Sizemore J see Calabrese JR
Skadhede S see Nielsen J
Skodol AE see Yen S
Slembarski R see Calabrese JR
Sluss PM see Lawson EA
Smit JH see Lamers F
Smith EG, Craig TJ, Ganoczy D, Walters HM, Valenstein M. Treatment of veterans with depression who died by suicide: timing and quality of care at last Veterans Health Administration visit. May 622–629
Smith SM see Pickering RP
Snow-Adami L see Kane JM
Soares CN see Lokuge S
Soek JH see Hong HJ
Soeteman DI, Verheul R, Meerman AMMA, Ziegler U, Rossum BV, Delimon J, Rijnierse P, Thunnissen M, Busschbach JJV, Kim JJ. Cost-effectiveness of psychotherapy for cluster C personality disorders: a decision-analytic model in the Netherlands. Jan 51–59
Sokolski K see Gitlin MJ
Solà R see Diez-Quevedo C
Solomon DA see Leon AC
Soltmann B see Strech D
Sommer IEC see Daalman K
Sparhawk R. In bipolar disorder beyond 10 weeks of treatment, the term *antidepressants* is a misnomer [letter]. June 871
Sparshatt A, Taylor D, Patel MX, Kapur S. Relationship between daily dose, plasma concentrations, dopamine receptor occupancy, and clinical response to quetiapine: a review. Aug 1108–1123
Sperling RA see Reiman EM
Spero DE see George DT
Spinhoven P see Lamers F
Spirito A see Topor DR; Vitiello B
Spitzer C see Löwe B; Terfehr K
Spitzer RL see Löwe B
Spyker DA see Allen MH
Stafford L, Berk M. Use of statins after a cardiac intervention is associated with reduced risk of subsequent depression: proof of concept for the inflammatory and oxidative hypotheses of depression? Sept 1229–1235
Stagno SJ. Review of Peteet JR, Lu FG, Narrow WE (eds): *Religious and Spiritual Issues in Psychiatric Diagnosis: A Research Agenda for* DSM-V. Dec 1699–1700
St-André E see Lespérance F
Stecker T see Fortney JC
Steeg S see Oude Voshaar RC
Steen NE, Methlie P, Lorentzen S, Hope S, Barrett EA, Larsson S, Mork E, Almås B, Løvås K, Agartz I, Melle I, Berg JP, Andreassen OA. Increased systemic cortisol metabolism in patients with schizophrenia and bipolar disorder: a mechanism for increased stress vulnerability? Nov 1515–1521
Stein MB, Roy-Byrne PP, Craske MG, Campbell-Sills L, Lang AJ, Golinelli D, Rose RD, Bystritsky A, Sullivan G, Sherbourne CD. Quality of and patient satisfaction with primary health care for anxiety disorders. July 970–976
Steiner M see Lokuge S
Stek ML see Oudega ML
Stenberg J-H see Tchoukhine E
Sterne JAC see Krogh J
Stewart JW see Barbee JG
Stieglitz R-D see Wirz-Justice A
Stinson FS see Pickering RP
Stone AM, Merlo LJ. Attitudes of college students toward mental illness stigma and the misuse of psychiatric medications. Feb 134–139
Stowe ZN see Suri R
Strain JJ. Review of Gabbard GO: *Long-Term Psychodynamic Psychotherapy: A Basic Text, 2nd ed.* Aug 1158
Strakowski SM. Review of Yatham LN, Maj M (eds): *Bipolar Disorder: Clinical and Neurobiological Foundations.* Oct 1433–1434
Strech D, Soltmann B, Weikert B, Bauer M, Pfennig A. Quality of reporting of randomized controlled trials of pharmacologic treatment of bipolar disorders: a systematic review. Sept 1214–1221
Streltzer J. Review of Ruiz P, Primm A: *Disparities in Psychiatric Care: Clinical and Cross-Cultural Perspectives.* Feb 264
Strober MA see Vitiello B
Stroup TS see Addington DE; Caroff SN
Stübner S, Grohmann R, Greil W. Reply to Baldessarini RJ: Suicidal risk during antidepressant treatment [letter]. May 722
Su T-P see Bai YM
Sublette ME, Ellis SP, Geant AL, Mann JJ. Meta-analysis of the effects of eicosapentaenoic acid (EPA) in clinical trials in depression. Dec 1577–1584
Sudak DM. Review of Wright JH, Turkington D, Kingdon DG, Basco MR: *Cognitive-Behavior Therapy for Severe Mental Illness: An Illustrated Guide.* Mar 420–421
Sudak HS. Review of Hollander E, Zohar J, Sirovataka PJ, Regier DA (eds): *Obsessive-Compulsive Spectrum Disorders: Refining the Research Agenda for* DSM-V. Sept 1286
Suddath R see Vitiello B
Sullivan G see Stein MB
Sunderajan P see Trivedi MH
Suri R, Hellemann G, Stowe ZN, Cohen LS, Aquino A, Altshuler LL. Prospective, naturalistic, blinded study of early neurobehavioral outcomes for infants following prenatal antidepressant exposure. July 1002–1007
Surman CBH, Roth T. Impact of stimulant pharmacotherapy on sleep quality: post hoc analyses of 2 large, double-blind, randomized, placebo-controlled trials. July 903–908
Suzuki T. Metabolic syndrome in inpatients treated with clozapine [letter with reply]. June 872–873
Suzuki T, Nomura K, Watanabe K. Risks of intermittent antipsychotic treatment in schizophrenia [letter with reply]. Jan 114
Swardfager W, Herrmann N, Marzolini S, Saleem M, Farber SB, Kiss A, Oh PI, Lanctôt KL. Major depressive disorder predicts completion, adherence, and outcomes in cardiac rehabilitation: a prospective cohort study of 195 patients with coronary artery disease. Sept 1181–1188
Swartz HA, Thase ME. Pharmacotherapy for the treatment of acute bipolar II depression: current evidence. Mar 356–366
Swartz MS see Addington DE; Caroff SN
Swenson LP see Topor DR
Szegedi A see Kane JM
Tabarés-Seisdedos R see González-Pinto A
Takala P see Tchoukhine E
Tamburrino M see Calabrese JR
Tan Y-L see Zhang W-F
Tanaka Y see Zanarini MC
Tandon R. Antipsychotics in the treatment of schizophrenia: an overview. Suppl 1, 4–8
Tanenberg-Karant M see Ruggero CJ
Tauber SC see Paulzen M
Taylor D see Sparshatt A
Tchoukhine E, Takala P, Hakko H, Raidma M, Putkonen H, Räsänen P, Terevnikov V, Stenberg J-H, Eronen M, Joffe G. Orlistat in clozapine- or olanzapine-treated patients with overweight or obesity: a 16-week open-label extension phase and both phases of a randomized controlled trial. Mar 326–330
Teba F see Usall J

Teboul E. Keeping 'em honest: the current crisis of confidence in antidepressants [letter with reply]. July 1015
Tedeschini E, Fava M, Papakostas GI. Placebo-controlled, antidepressant clinical trials cannot be shortened to less than 4 weeks' duration: a pooled analysis of randomized clinical trials employing a diagnostic odds ratio–based approach. Jan 98–103
Tedeschini E, Levkovitz Y, Iovieno N, Ameral VE, Nelson JC, Papakostas GI. Efficacy of antidepressants for late-life depression: a meta-analysis and meta-regression of placebo-controlled randomized trials. Dec 1660–1668
Tedeschini E see Iovieno N; Levkovitz Y
Teipel SJ see Buerger K
Temple RJ see Laughren TP
Terao T. Can pindolol really enhance antidepressant effect? [letter with reply] Nov 1558
Terevnikov V see Tchoukhine E
Terfehr K, Wolf OT, Schlosser N, Fernando SC, Otte C, Muhtz C, Beblo T, Driessen M, Spitzer C, Löwe B, Wingenfeld K. Effects of acute hydrocortisone administration on declarative memory in patients with major depression: a placebo-controlled, double-blind crossover study. Dec 1644–1650
Terman M see Wirz-Justice A
Thampi A see Yung AR
Thase ME. Role of neurobiologic processes in symptoms of depression. Feb e08
Thase ME. Treatment-resistant depression: prevalence, risk factors, and treatment strategies. May e18
Thase ME see Brooks JO III; Carpenter DJ; Cristancho P; Swartz HA
Thein K see Cohen-Mansfield J
Thewissen V see Lataster J
Thompson AD see Yung AR
Thompson PM see Barbee JG
Thompson TR see Barbee JG
Thunnissen M see Soeteman DI
Timpano KR, Exner C, Glaesmer H, Rief W, Keshaviah A, Brähler E, Wilhelm S. Epidemiology of the proposed *DSM-5* hoarding disorder: exploration of the acquisition specifier, associated features, and distress. June 780–786
Tohen M see Kemp DE; Salvatore P
Topor DR, Swenson LP, Liguori GM, Spirito A, Lowenhaupt EA, Hunt JI. Problematic Video Game Use Scale: initial psychometric properties with psychiatrically hospitalized adolescents. Dec 1611–1615
Tordjman S see Gerardin P
Torres AR, Ramos-Cerqueira ATA, Ferrão YA, Fontenelle LF, do Rosário MC, Miguel EC. Suicidality in obsessive-compulsive disorder: prevalence and relation to symptom dimensions and comorbid conditions. Jan 17–26
Tossani E see Grandi S
Tran QV see Weisler RH
Trial 144 Study Investigators see Weisler RH
Triffleman EG see Crisanti AS
Trivedi MH, Greer TL, Church TS, Carmody TJ, Grannemann BD, Galper DI, Dunn AL, Earnest CP, Sunderajan P, Henley SS, Blair SN. Exercise as an augmentation treatment for nonremitted major depressive disorder: a randomized, parallel dose comparison. May 677–684
Trivedi MH, Wisniewski SR, Morris DW, Fava M, Gollan JK, Warden D, Nierenberg AA, Gaynes BN, Husain MM, Luther JF, Zisook S, Rush AJ. Concise Health Risk Tracking Scale: a brief self-report and clinician rating of suicidal risk. June 757–764
Trivedi MH, Wisniewski SR, Morris DW, Fava M, Kurian BT, Gollan JK, Nierenberg AA, Warden D, Gaynes BN, Luther JF, Rush AJ. Concise Associated Symptoms Tracking Scale: a brief self-report and clinician rating of symptoms associated with suicidality. June 765–774
Trivedi MH see Harding KJK; Nierenberg AA; Shelton RC; Weisler RH; Zisook S
Trollor JN see Gurrera RJ
Tsai S-Y see Kuo C-J
Tsouli S see Peritogiannis V
Tsuang J see Makhinson M
Turecki G see Lespérance F
Turner JB see Comer JS
Tzur D see Nacasch N
Uher R, Mors O, Rietschel M, Rajewska-Rager A, Petrovic A, Zobel A, Henigsberg N, Mendlewicz J, Aitchison KJ, Farmer A, McGuffin P. Early and delayed onset of response to antidepressants in individual trajectories of change during treatment of major depression: a secondary analysis of data from the Genome-Based Therapeutic Drugs for Depression (GENDEP) Study. Nov 1478–1484
Umhau JC see George DT
Unger EF see Laughren TP
Usall J, Huerta-Ramos E, Iniesta R, Cobo J, Araya S, Roca M, Serrano-Blanco A, Teba F, Ochoa S. Raloxifene as an adjunctive treatment for postmenopausal women with schizophrenia: a double-blind, randomized, placebo-controlled trial. Nov 1552–1557
Uspenskaya O see Buerger K
Vaiva G see Chaudieu I
Valenstein M see Brower KJ; Smith EG
Van Ameringen M, Mancini C, Patterson B. Impact of changing diagnostic criteria in posttraumatic stress disorder in a Canadian epidemiologic sample. Aug 1034–1041
van Balkom AJLM see Lamers F
van den Noort M, Bosch P. Schizophrenia-related outpatient treatment of Medicaid-financed patients after hospital discharge [letter with reply]. Jan 113
Vanderburg DG see Karayal ON; Sachs GS
van der Does AJW see Wiersma JE
Van Dorn RA, Andel R, Boaz TL, Desmarais SL, Chandler K, Becker MA, Howe A. Risk of arrest in persons with schizophrenia and bipolar disorder in a Florida Medicaid program: the role of atypical antipsychotics, conventional neuroleptics, and routine outpatient behavioral health services. Apr 502–508
van Elst LT, Klöppel S, Rauer S. Voltage-gated potassium channel/LGI1 antibody–associated encephalopathy may cause brief psychotic disorder [letter]. May 722–723
van Exel E see Oudega ML
Van Meter AR, Moreira ALR, Youngstrom EA. Meta-analysis of epidemiologic studies of pediatric bipolar disorder. Sept 1250–1256
van Oppen P see Lamers F; Wiersma JE
van Os J see Lataster J
van Schaik DJF see Wiersma JE
van Wattum PJ. Review of Kaminer Y, Winters KC (eds): *Clinical Manual of Adolescent Substance Abuse Treatment*. Dec 1700–1701
Varallo-Bedarida G see Baghai TC
Vázquez G see Frye MA
Velamoor VR see Gurrera RJ
Verdes E see Nuevo R
Verheul R see Soeteman DI
Vieta E see Cruz N; Frye MA; González-Pinto A; Kapczinski F; Salvatore P
Vitiello B, Emslie G, Clarke G, Wagner KD, Asarnow JR, Keller MB, Birmaher B, Ryan ND, Kennard B, Mayes TL, DeBar L, Lynch F, Dickerson J, Strober M, Suddath R, McCracken JT, Spirito A, Onorato M, Zelazny J, Porta G, Iyengar S, Brent DA. Long-term outcome of adolescent depression initially resistant to selective serotonin reuptake inhibitor treatment: a follow-up study of the TORDIA sample. Mar 388–396
Vivek S. Review of Leigh H: *Genes, Memes, Culture, and Mental Illness: Toward an Integrative Model*. Dec 1699
Vogelzangs N, Beekman ATF, Boelhouwer IG, Bandinelli S, Milaneschi Y, Ferrucci L, Penninx BWJH. Metabolic depression: a chronic depressive subtype? findings from the InCHIANTI study of older persons. May 598–604
Volavka J, Czobor P, Derks EM, Bitter I, Libiger J, Kahn RS, Fleischhacker WW, EUFEST Study Group. Efficacy of antipsychotic drugs against hostility in the European First-Episode Schizophrenia Trial (EUFEST). July 955–961
Volpe D, Patwa HS. Review of Weiner WJ, Goetz CG Shin RK, Lewis SL (eds): *Neurology for the Non-Neurologist, 6th ed.* Oct 1432–1433
von Schacky C see Baghai TC
von Wilmsdorff M see Gaebel W
Vythilingam M see Bonne O
Wagner KD. Controversial issues in child psychiatry [introduction]. June 835
Wagner KD. Impact of mood disorders [introduction]. Mar 376–377
Wagner KD. Potpourri of timely topics [introduction]. Sept 1248–1249
Wagner KD see McIntyre RS; Vitiello B
Wakefield JC, First MB. Treatment outcome for bereavement-excluded depression: results of the study by Corruble et al are not what they seem [letter with reply]. Aug 1155
Walker EF see Compton MT
Walker JR see Kinley DJ
Wall CA, Croarkin PE, Sim LA, Husain MM, Janicak PG, Kozel FA, Emslie GJ, Dowd SM, Sampson SM. Adjunctive use of repetitive transcranial magnetic stimulation in depressed adolescents: a prospective, open pilot study. Sept 1263–1269

Walsh Z see Yen S
Walters HM see Smith EG
Wang S-J see Laughren TP
Wang WV see Kemp DE
Wang Y see Laughren TP
Wang Z see Gao K
Warden D see Trivedi MH
Waschbusch DA see Waxmonsky JG
Watanabe K see Suzuki T
Watanabe N, Furukawa TA, Shimodera S, Morokuma I, Katsuki F, Fujita H, Sasaki M, Kawamura C, Perlis ML. Brief behavioral therapy for refractory insomnia in residual depression: an assessor-blind, randomized controlled trial. Dec 1651–1658
Watson CB see Gurrera RJ
Wattjes MP see Oudega ML
Waxmonsky JG, Waschbusch DA, Glatt SJ, Faraone SV. Prediction of placebo response in 2 clinical trials of lisdexamfetamine dimesylate for the treatment of ADHD. Oct 1366–1375
Weatherley BD see Shemesh E
Webb RT see Laursen TM
Weber-Hamann B see Hummel J
Wechsler RS see Pollack MH
Weiden PJ see Glick ID
Weikert B see Strech D
Weisler RH, Khan A, Trivedi MH, Yang H, Eudicone JM, Pikalov A, Tran QV, Berman RM, Carlson BX. Analysis of suicidality in pooled data from 2 double-blind, placebo-controlled aripiprazole adjunctive therapy trials in major depressive disorder. Apr 548–555
Weisler RH, Nolen WA, Neijber A, Hellqvist Å, Paulsson B, Trial 144 Study Investigators. Continuation of quetiapine versus switching to placebo or lithium for maintenance treatment of bipolar I disorder (Trial 144: a randomized controlled study). Nov 1452–1464
Weisler RH see Paulozzi LJ
Weiss PS see Compton MT
Weissman SH. Review of Frankland AG: *The Little Psychotherapy Book: Object Relations in Practice*. Sept 1288
Wendland J see Gerardin P
Wessel TC see Fava M
Westen D see Bradley B
Westphal S see Hummel J
Wetherell JL see Mittal D
Whalen H see Athanasiou MC; Khan A
Wiersma JE, van Oppen P, van Schaik DJF, van der Does AJW, Beekman ATF, Penninx BWJH. Psychological characteristics of chronic depression: a longitudinal cohort study. Mar 288–294
Wiesmann M see Frodl T
Wilens TE see Hua LL
Wilhelm S see Timpano KR
Wilkinson JR see Gurrera RJ
Williams JBW see Löwe B
Williams JHH see Lepping P
Wilson A see Fava M
Wilson K see Calabrese JR
Wingenfeld K see Löwe B; Terfehr K
Wirz-Justice A, Bader A, Frisch U, Stieglitz R-D, Alder J, Bitzer J, Hösli I, Jazbec S, Benedetti F, Terman M, Wisner KL, Riecher-Rössler A. Randomized, double-blind, placebo-controlled study of light therapy for antepartum depression. July 986–993
Wise TN. Review of Black DW, Andreasen NC: *Introductory Textbook of Psychiatry, 5th ed.* Aug 1159
Wisner KL see Sit D; Wirz-Justice A
Wisniewski SR see Lespérance F; Sit D; Zisook S
Witte J see Desseilles M
Wittmann CW see Sachs GS
Wittmann L see Schnyder U
Wojnar J see Brower KJ
Wojnar M see Brower KJ
Wolf OT see Terfehr K
Wölwer W see Gaebel W
Wong P see Hua LL
Woo J-M, Gibbons RD, Qin P, Komarow H, Kim JB, Rogers CA, Mann JJ, Postolache TT. Suicide and prescription rates of intranasal corticosteroids and nonsedating antihistamines for allergic rhinitis: an ecological study. Oct 1423–1428
Woolley JD, Khan BK, Murthy NK, Miller BL, Rankin KP. Diagnostic challenge of psychiatric symptoms in neurodegenerative disease: rates of and risk factors for prior psychiatric diagnosis in patients with early neurodegenerative disease. Feb 126–133
Worthington JJ see Pollack MH
Wozniak J see Biederman J; Hua LL
Wu H-R see Zhang W-F
Yager J. Review of Grilo CM, Mitchell JE (eds): *The Treatment of Eating Disorders: A Clinical Handbook*. May 727–728
Yang H see Weisler RH
Yang P see Khin NA; Laughren TP
Yang Y see Bourgeois JA; Khin NA
Yaseen ZS see Katz C
Yehuda R see Shemesh E
Yen S, Shea MT, Walsh Z, Edelen MO, Hopwood CJ, Markowitz JC, Ansell EB, Morey LC, Grilo CM, Sanislow CA, Skodol AE, Gunderson JG, Zanarini MC, McGlashan TH. Self-harm subscale of the Schedule for Nonadaptive and Adaptive Personality (SNAP): predicting suicide attempts over 8 years of follow-up. Nov 1522–1528
Yip PSF see Chen Y-Y; Cheng Q
Youn SJ see Chen JA
Young D see Zimmerman M
Youngstrom EA see Axelson DA; Frazier TW; Van Meter AR
Yu AP see Signorovitch J
Yu B see Laughren TP
Yuan P see Bonne O
Yung AR, Phillips LJ, Nelson B, Francey SM, PanYuen H, Simmons MB, Ross ML, Kelly D, Baker K, Amminger GP, Berger G, Thompson AD, Thampi A, McGorry PD. Randomized controlled trial of interventions for young people at ultra high risk for psychosis: 6-month analysis. Apr 430–440
Zajecka JM see Fava M
Zanarini MC, Schulz SC, Detke HC, Tanaka Y, Zhao F, Lin D, Deberdt W, Kryzhanovskaya L, Corya S. Dose comparison of olanzapine for the treatment of borderline personality disorder: a 12-week randomized, double-blind, placebo-controlled study. Oct 1353–1362
Zanarini MC see Yen S
Zarate CA Jr see Salvatore P
Zarrow ME see Shiovitz TM
Zelazny J see Vitiello B
Zhang H see Laughren TP
Zhang L see Laughren TP
Zhang W-F, Tan Y-L, Zhang X-Y, Chan RCK, Wu H-R, Zhou D-F. Extract of *Ginkgo biloba* treatment for tardive dyskinesia in schizophrenia: a randomized, double-blind, placebo-controlled trial. May 615–621
Zhang X-Y see Zhang W-F
Zhao F see Zanarini MC
Zhao J see Kane JM
Zhou D-F see Zhang W-F
Ziegler U see Soeteman DI
Zimbroff DL see Allen MH
Zimmerman B see Calarge CA
Zimmerman M, Chelminski I, Young D, Dalrymple K, Martinez J. Does *DSM-IV* already capture the dimensional nature of personality disorders? Oct 1333–1339
Zineh I see Laughren TP
Zipursky RB see Agid O
Zisook S, Lesser IM, Lebowitz B, Rush AJ, Kallenberg G, Wisniewski SR, Nierenberg AA, Fava M, Luther JF, Morris DW, Trivedi MH. Effect of antidepressant medication treatment on suicidal ideation and behavior in a randomized trial: an exploratory report from the Combining Medications to Enhance Depression Outcomes Study. Oct 1322–1332
Zisook S, Reynolds CF III, Pies R, Simon NM, Lebowitz B, Shear MK. Reply to Clayton PJ: Back to "normal bereavement" [letter]. Feb 260–261
Zisook S see Trivedi MH
Zitman FG see Lamers F
Zobel A see Uher R
Zohar J see Nacasch N
Zorrilla I see González-Pinto A
Zou W see Athanasiou MC